```
=> e kozel thomas r/au
E1            7     KOZEL THOMAS/AU
E2            2     KOZEL THOMAS H/AU
E3          160 --> KOZEL THOMAS R/AU
E4            1     KOZEL THOMAS RANDALL/AU
E5            2     KOZEL TOMAS/AU
E6            2     KOZEL TSEV A L/AU
E7           11     KOZEL TSEV L I/AU
E8            2     KOZEL TSEV M L/AU
E9           56     KOZEL TSEV V L/AU
E10           1     KOZEL TSEVA I M/AU
E11           1     KOZEL TSOV N P/AU
E12           3     KOZEL TSOVA N P/AU

=> s e3-e4 and anthrac?
L1            3 ("KOZEL THOMAS R"/AU OR "KOZEL THOMAS RANDALL"/AU) AND ANTHRAC?

=> s e3-e4 and antrax
L2            0 ("KOZEL THOMAS R"/AU OR "KOZEL THOMAS RANDALL"/AU) AND ANTRAX

=> s e3-e4 and anthrax
L3            3 ("KOZEL THOMAS R"/AU OR "KOZEL THOMAS RANDALL"/AU) AND ANTHRAX

=> s e3-e4 and (anthrac? or anthrax)
L4            3 ("KOZEL THOMAS R"/AU OR "KOZEL THOMAS RANDALL"/AU) AND (ANTHRAC?
                 OR ANTHRAX)

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5             1 DUP REM L4 (2 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y


L5   ANSWER 1 OF 1  BIOSIS  COPYRIGHT (c) 2005 The Thomson Corporation  on STN
     DUPLICATE 1
AN   2004:290378  BIOSIS
DN   PREV200400292919
TI   mAbs to Bacillus anthracis capsular antigen for immunoprotection
     in anthrax and detection of antigenemia.
AU   Kozel, Thomas R. [Reprint Author]; Murphy, William J.; Brandt,
     Suzanne; Blazar, Bruce R.; Lovchik, Julie A.; Thorkildson, Peter;
     Percival, Ann; Lyons, C. Rick
CS   Sch MedDept Microbiol and Immunol, Univ Nevada, Reno, NV, 89557, USA
     trkozel@med.unr.edu
SO   Proceedings of the National Academy of Sciences of the United States of
     America, (April 6 2004) Vol. 101, No. 14, pp. 5042-5047. print.
     ISSN: 0027-8424 (ISSN print)
DT   Article
LA   English
ED   Entered STN: 23 Jun 2004
     Last Updated on STN: 23 Jun 2004
AB   Bacillus anthracis is surrounded by an antiphagocytic
     polypeptide capsule composed Of Poly gamma-D-glutamic acid (gammaDPGA).
     gammaDPGA has been identified recently as a potential target for vaccine
     development.  Studies of the role of gammaDPGA in disease have been
     hampered by the poor Ab response to this antigen and the lack of
     immunochemical reagents.  As a consequence, neither the extent of
     gammaDPGA production during anthrax nor the protective activity
     of gammaDPGA Abs in inhalation anthrax are known.  Here we
     report production of IgG Abs to gammaDPGA in mice following an
     immunization regimen using gammaDPGA in combination with agonist mAbs to
     CD40. mAbs were produced that are specific for gammaDPGA.  Passive
     immunization with gammaDPGA mAbs protected > 90% of mice in a pulmonary
     model of anthrax that was lethal in control mice (P < 0.0001).
     Use of gammaDPGA mAb in an antigen detection immunoassay found that the
     appearance of gammaDPGA in serum coincided with the emergence of
     bacteremia.  These studies identify CD40 stimulation as a means for
```

production of Ab and generation of mAbs against a weakly immunogenic antigen and demonstrate that the capsule is an effective target for immunoprotection and for antigen detection in the diagnosis of **anthrax**.

```
=> e murphy william j/au
E1            3     MURPHY WILLIAM I/AU
E2            1     MURPHY WILLIAM IGNATIUS III/AU
E3          588 --> MURPHY WILLIAM J/AU
E4            8     MURPHY WILLIAM JAMES/AU
E5           28     MURPHY WILLIAM JOHN/AU
E6            5     MURPHY WILLIAM JOSEPH/AU
E7           27     MURPHY WILLIAM K/AU
E8           47     MURPHY WILLIAM L/AU
E9            1     MURPHY WILLIAM LEO/AU
E10          91     MURPHY WILLIAM M/AU
E11           1     MURPHY WILLIAM MARK/AU
E12           1     MURPHY WILLIAM MARSHALL/AU

=> s e3-e6 and (anthrac? or anthrax)
L6            6 ("MURPHY WILLIAM J"/AU OR "MURPHY WILLIAM JAMES"/AU OR "MURPHY
                WILLIAM JOHN"/AU OR "MURPHY WILLIAM JOSEPH"/AU) AND (ANTHRAC?
                OR ANTHRAX)

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7             4 DUP REM L6 (2 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y


L7   ANSWER 1 OF 4  BIOSIS  COPYRIGHT (c) 2005 The Thomson Corporation  on STN
     DUPLICATE 1
AN   2004:290378  BIOSIS
DN   PREV200400292919
TI   mAbs to Bacillus anthracis capsular antigen for immunoprotection
     in anthrax and detection of antigenemia.
AU   Kozel, Thomas R. [Reprint Author]; Murphy, William J.; Brandt,
     Suzanne; Blazar, Bruce R.; Lovchik, Julie A.; Thorkildson, Peter;
     Percival, Ann; Lyons, C. Rick
CS   Sch MedDept Microbiol and Immunol, Univ Nevada, Reno, NV, 89557, USA
     trkozel@med.unr.edu
SO   Proceedings of the National Academy of Sciences of the United States of
     America, (April 6 2004) Vol. 101, No. 14, pp. 5042-5047. print.
     ISSN: 0027-8424 (ISSN print).
DT   Article
LA   English
ED   Entered STN: 23 Jun 2004
     Last Updated on STN: 23 Jun 2004
AB   Bacillus anthracis is surrounded by an antiphagocytic
     polypeptide capsule composed Of Poly gamma-D-glutamic acid (gammaDPGA).
     gammaDPGA has been identified recently as a potential target for vaccine
     development.  Studies of the role of gammaDPGA in disease have been
     hampered by the poor Ab response to this antigen and the lack of
     immunochemical reagents.  As a consequence, neither the extent of
     gammaDPGA production during anthrax nor the protective activity
     of gammaDPGA Abs in inhalation anthrax are known.  Here we
     report production of IgG Abs to gammaDPGA in mice following an
     immunization regimen using gammaDPGA in combination with agonist mAbs to
     CD40. mAbs were produced that are specific for gammaDPGA.  Passive
     immunization with gammaDPGA mAbs protected > 90% of mice in a pulmonary
     model of anthrax that was lethal in control mice (P < 0.0001).
     Use of gammaDPGA mAb in an antigen detection immunoassay found that the
     appearance of gammaDPGA in serum coincided with the emergence of
     bacteremia.  These studies identify CD40 stimulation as a means for
     production of Ab and generation of mAbs against a weakly immunogenic
     antigen and demonstrate that the capsule is an effective target for
```

immunoprotection and for antigen detection in the diagnosis of **anthrax**.

L7 ANSWER 2 OF 4 USPATFULL on STN
AN 2003:99195 USPATFULL
TI Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
IN **Murphy, William J.**, Reno, NV, UNITED STATES
Wiltrout, Robert, Woodsboro, MD, UNITED STATES
Blazar, Bruce, Golden Valley, MN, UNITED STATES
Wilson, Susan E., Alameda, CA, UNITED STATES
PI US 2003068299 A1 20030410
AI US 2002-226959 A1 20020823 (10)
PRAI US 2001-314342P 20010823 (60)
DT Utility
FS APPLICATION
LREP LEYDIG VOIT & MAYER, LTD, TWO PRUDENTIAL PLAZA, SUITE 4900, 180 NORTH STETSON AVENUE, CHICAGO, IL, 60601-6780
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1003
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a method of treating or preventing a pathologic state in a mammal. The method comprises administering to the mammal a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system. The promoter of T-cell expansion and inducer of CD40 stimulation are administered in synergistically effective amounts to treat or prevent the pathologic state in the mammal. The invention also provides a method of assessing the effectiveness of treatment of a pathologic state in a mammal, wherein the mammal has been administered a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system. The method comprises measuring the level of at least one antibody in a test sample obtained from the mammal, which at least one antibody is specific for an antigen that is known to be associated with the pathologic state, and wherein the level of the at least one antibody is indicative of the effectiveness of treatment of the pathologic state in the mammal.

L7 ANSWER 3 OF 4 USPATFULL on STN
AN 2003:129958 USPATFULL
TI Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation
IN Howard, O. M. Zack, Frederick, MD, United States
Oppenheim, Joost J., Bethesda, MD, United States
**Murphy, William J.**, Frederick, MD, United States
Sausville, Edward A., Silver Spring, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 6562859 B1 20030513
WO 9927939 19990610
AI US 2000-555733 20000804 (9)
WO 1998-US25811 19981204
PRAI US 1997-67526P 19971204 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jones, Dwayne C.
LREP Leydig, Voit & Mayer, Ltd.
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 957
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of using a ureido derivative of a poly-4-amino-2-carboxy-1-methyl pyrrole or a pharmaceutically acceptable salt thereof to inhibit inflammation, particularly non-TNF-α dependent inflammation, in a mammal.

L7 ANSWER 4 OF 4 USPATFULL on STN
AN 89:80698 USPATFULL
TI Electrophotographic photoreceptor containing a toner release material
IN **Murphy, William J.**, San Jose, CA, United States
PA X-Solve, Inc., San Jose, CA, United States (U.S. corporation)
PI US 4869982 19890926
AI US 1987-45682 19870430 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Goodrow, John L.
LREP Perman & Green
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An organic photosensitive member for use in electrophotography comprising a conductive substrate and one or more electrically operative layers is disclosed. The imaging layer of the member contains from about 0.5 to about 20 percent of a toner release agent selected from the group of materials composed of stearates, silicon oxides, and fluorocarbons.

=> e brandt suzanne/au
E1 5 BRANDT SUSAN R/AU
E2 1 BRANDT SUSANNE/AU
E3 17 --> BRANDT SUZANNE/AU
E4 3 BRANDT SVEN/AU
E5 2 BRANDT SVEN E/AU
E6 1 BRANDT SYLVIA J/AU
E7 1892 BRANDT T/AU
E8 30 BRANDT T A/AU
E9 2 BRANDT T B/AU
E10 55 BRANDT T D/AU
E11 3 BRANDT T E/AU
E12 2 BRANDT T F/AU

=> s e2-e3 and (anthrac? or anthrax)
L8 3 ("BRANDT SUSANNE"/AU OR "BRANDT SUZANNE"/AU) AND (ANTHRAC? OR ANTHRAX)

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9 1 DUP REM L8 (2 DUPLICATES REMOVED)

=> d bib ab

L9 ANSWER 1 OF 1 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 1
AN 2004:290378 BIOSIS
DN PREV200400292919
TI mAbs to Bacillus **anthracis** capsular antigen for immunoprotection in **anthrax** and detection of antigenemia.
AU Kozel, Thomas R. [Reprint Author]; Murphy, William J.; **Brandt, Suzanne**; Blazar, Bruce R.; Lovchik, Julie A.; Thorkildson, Peter; Percival, Ann; Lyons, C. Rick
CS Sch MedDept Microbiol and Immunol, Univ Nevada, Reno, NV, 89557, USA
trkozel@med.unr.edu
SO Proceedings of the National Academy of Sciences of the United States of America, (April 6 2004) Vol. 101, No. 14, pp. 5042-5047. print.
ISSN: 0027-8424 (ISSN print).
DT Article
LA English
ED Entered STN: 23 Jun 2004
Last Updated on STN: 23 Jun 2004
AB Bacillus **anthracis** is surrounded by an antiphagocytic polypeptide capsule composed Of Poly gamma-D-glutamic acid (gammaDPGA). gammaDPGA has been identified recently as a potential target for vaccine development. Studies of the role of gammaDPGA in disease have been

hampered by the poor Ab response to this antigen and the lack of immunochemical reagents. As a consequence, neither the extent of gammaDPGA production during **anthrax** nor the protective activity of gammaDPGA Abs in inhalation **anthrax** are known. Here we report production of IgG Abs to gammaDPGA in mice following an immunization regimen using gammaDPGA in combination with agonist mAbs to CD40. mAbs were produced that are specific for gammaDPGA. Passive immunization with gammaDPGA mAbs protected > 90% of mice in a pulmonary model of **anthrax** that was lethal in control mice ($P < 0.0001$). Use of gammaDPGA mAb in an antigen detection immunoassay found that the appearance of gammaDPGA in serum coincided with the emergence of bacteremia. These studies identify CD40 stimulation as a means for production of Ab and generation of mAbs against a weakly immunogenic antigen and demonstrate that the capsule is an effective target for immunoprotection and for antigen detection in the diagnosis of **anthrax**.

```
=> e thorkildson peter/au
E1            1     THORKILDSON JOEL B/AU
E2           20     THORKILDSON P/AU
E3           14 --> THORKILDSON PETER/AU
E4            1     THORKILDSON R J/AU
E5            1     THORKILDSON ROBERT J/AU
E6            5     THORKILGAARD O/AU
E7            1     THORKILSEN B/AU
E8            2     THORKILSEN GEIR/AU
E9            1     THORKINGTON P/AU
E10           1     THORKLAKSON R H/AU
E11           1     THORKSHAUGE H/AU
E12           1     THORL F/AU

=> s e2-e3 and (anthrac? or anthrax)
L10           6 ("THORKILDSON P"/AU OR "THORKILDSON PETER"/AU) AND (ANTHRAC? OR
                ANTHRAX)

=> dup rem l10
PROCESSING COMPLETED FOR L10
L11            1 DUP REM L10 (5 DUPLICATES REMOVED)

=> d bib ab

L11  ANSWER 1 OF 1  BIOSIS  COPYRIGHT (c) 2005 The Thomson Corporation  on STN
     DUPLICATE 1
AN   2004:290378  BIOSIS
DN   PREV200400292919
TI   mAbs to Bacillus anthracis capsular antigen for immunoprotection
     in anthrax and detection of antigenemia.
AU   Kozel, Thomas R. [Reprint Author]; Murphy, William J.; Brandt, Suzanne;
     Blazar, Bruce R.; Lovchik, Julie A.; Thorkildson, Peter;
     Percival, Ann; Lyons, C. Rick
CS   Sch MedDept Microbiol and Immunol, Univ Nevada, Reno, NV, 89557, USA
     trkozel@med.unr.edu
SO   Proceedings of the National Academy of Sciences of the United States of
     America, (April 6 2004) Vol. 101, No. 14, pp. 5042-5047. print.
     ISSN: 0027-8424 (ISSN print).
DT   Article
LA   English
ED   Entered STN: 23 Jun 2004
     Last Updated on STN: 23 Jun 2004
AB   Bacillus anthracis is surrounded by an antiphagocytic
     polypeptide capsule composed Of Poly gamma-D-glutamic acid (gammaDPGA).
     gammaDPGA has been identified recently as a potential target for vaccine
     development. Studies of the role of gammaDPGA in disease have been
     hampered by the poor Ab response to this antigen and the lack of
     immunochemical reagents. As a consequence, neither the extent of
     gammaDPGA production during anthrax nor the protective activity
     of gammaDPGA Abs in inhalation anthrax are known. Here we
     report production of IgG Abs to gammaDPGA in mice following an
```

immunization regimen using gammaDPGA in combination with agonist mAbs to CD40. mAbs were produced that are specific for gammaDPGA. Passive immunization with gammaDPGA mAbs protected > 90% of mice in a pulmonary model of **anthrax** that was lethal in control mice (P < 0.0001). Use of gammaDPGA mAb in an antigen detection immunoassay found that the appearance of gammaDPGA in serum coincided with the emergence of bacteremia. These studies identify CD40 stimulation as a means for production of Ab and generation of mAbs against a weakly immunogenic antigen and demonstrate that the capsule is an effective target for immunoprotection and for antigen detection.in the diagnosis of **anthrax**.

```
=> e percival ann/au
E1            2     PERCIVAL ANDREW/AU
E2            2     PERCIVAL ANJA C/AU
E3            8 --> PERCIVAL ANN/AU
E4            5     PERCIVAL ANN L/AU
E5            7     PERCIVAL B/AU
E6            1     PERCIVAL BAANDON K/AU
E7            1     PERCIVAL BARKER K/AU
E8            5     PERCIVAL BRANDON K/AU
E9            1     PERCIVAL BRIAN/AU
E10          52     PERCIVAL C/AU
E11           1     PERCIVAL C B/AU
E12           1     PERCIVAL C C/AU

=> s e3-e4 and (anthrac? or anthrax)
L12           3 ("PERCIVAL ANN"/AU OR "PERCIVAL ANN L"/AU) AND (ANTHRAC? OR
                ANTHRAX)

=> dup rem l12
PROCESSING COMPLETED FOR L12
L13            1 DUP REM L12 (2 DUPLICATES REMOVED)

=> d bib ab

L13  ANSWER 1 OF 1  BIOSIS  COPYRIGHT (c) 2005 The Thomson Corporation  on STN
     DUPLICATE 1
AN   2004:290378  BIOSIS
DN   PREV200400292919
TI   mAbs to Bacillus anthracis capsular antigen for immunoprotection
     in anthrax and detection of antigenemia.
AU   Kozel, Thomas R. [Reprint Author]; Murphy, William J.; Brandt, Suzanne;
     Blazar, Bruce R.; Lovchik, Julie A.; Thorkildson, Peter; Percival,
     Ann; Lyons, C. Rick
CS   Sch MedDept Microbiol and Immunol, Univ Nevada, Reno, NV, 89557, USA
     trkozel@med.unr.edu
SO   Proceedings of the National Academy of Sciences of the United States of
     America, (April 6 2004) Vol. 101, No. 14, pp. 5042-5047. print.
     ISSN: 0027-8424 (ISSN print).
DT   Article
LA   English
ED   Entered STN: 23 Jun 2004
     Last Updated on STN: 23 Jun 2004
AB   Bacillus anthracis is surrounded by an antiphagocytic
     polypeptide capsule composed Of Poly gamma-D-glutamic acid (gammaDPGA).
     gammaDPGA has been identified recently as a potential target for vaccine
     development. Studies of the role of gammaDPGA in disease have been
     hampered by the poor Ab response to this antigen and the lack of
     immunochemical reagents. As a consequence, neither the extent of
     gammaDPGA production during anthrax nor the protective activity
     of gammaDPGA Abs in inhalation anthrax are known. Here we
     report production of IgG Abs to gammaDPGA in mice following an
     immunization regimen using gammaDPGA in combination with agonist mAbs to
     CD40. mAbs were produced that are specific for gammaDPGA. Passive
     immunization with gammaDPGA mAbs protected > 90% of mice in a pulmonary
     model of anthrax that was lethal in control mice (P < 0.0001).
     Use of gammaDPGA mAb in an antigen detection immunoassay found that the
```

appearance of gammaDPGA in serum coincided with the emergence of bacteremia. These studies identify CD40 stimulation as a means for production of Ab and generation of mAbs against a weakly immunogenic antigen and demonstrate that the capsule is an effective target for immunoprotection and for antigen detection in the diagnosis of **anthrax**.

```
=> e blazar bruce r/au
E1            1     BLAZAR BRUCE B/AU
E2            1     BLAZAR BRUCE L/AU
E3          518 --> BLAZAR BRUCE R/AU
E4            2     BLAZAR H A/AU
E5            1     BLAZAR J M/AU
E6            7     BLAZAR JOSEPH E/AU
E7            3     BLAZAR M/AU
E8            1     BLAZAR N E/AU
E9           11     BLAZAR P/AU
E10          27     BLAZAR P E/AU
E11           1     BLAZAR PHILIP/AU
E12           5     BLAZAR PHILIP E/AU

=> s e3 and (anthrac? or anthrax)
L14           3 "BLAZAR BRUCE R"/AU AND (ANTHRAC? OR ANTHRAX)

=> dup rem l14
PROCESSING COMPLETED FOR L14
L15           1 DUP REM L14 (2 DUPLICATES REMOVED)

=> d

L15  ANSWER 1 OF 1  BIOSIS  COPYRIGHT (c) 2005 The Thomson Corporation  on STN
     DUPLICATE 1
AN   2004:290378  BIOSIS
DN   PREV200400292919
TI   mAbs to Bacillus anthracis capsular antigen for immunoprotection
     in anthrax and detection of antigenemia.
AU   Kozel, Thomas R. [Reprint Author]; Murphy, William J.; Brandt, Suzanne;
     Blazar, Bruce R.; Lovchik, Julie A.; Thorkildson, Peter; Percival,
     Ann; Lyons, C. Rick
CS   Sch MedDept Microbiol and Immunol, Univ Nevada, Reno, NV, 89557, USA
     trkozel@med.unr.edu
SO   Proceedings of the National Academy of Sciences of the United States of
     America, (April 6 2004) Vol. 101, No. 14, pp. 5042-5047. print.
     ISSN: 0027-8424 (ISSN print).
DT   Article
LA   English
ED   Entered STN: 23 Jun 2004
     Last Updated on STN: 23 Jun 2004


=> e lovchik julie a/au
E1            1     LOVCHIK JUDY C/AU
E2            5     LOVCHIK JULIE/AU
E3            9 --> LOVCHIK JULIE A/AU
E4            1     LOVCHIK M A/AU
E5            1     LOVCHIK MARTIN A/AU
E6            1     LOVCHIKO GN/AU
E7            1     LOVCHIKO NN/AU
E8            2     LOVCHIKO VA/AU
E9            3     LOVCHIKOV A A/AU
E10           5     LOVCHIKOV A K/AU
E11           3     LOVCHIKOV A N/AU
E12           1     LOVCHIKOV A P/AU

=> s e2-e3 and (anthrac? or anthrax)
L16           7 ("LOVCHIK JULIE"/AU OR "LOVCHIK JULIE A"/AU) AND (ANTHRAC? OR
                ANTHRAX)
```

=> dup rem l16
PROCESSING COMPLETED FOR L16
L17 2 DUP REM L16 (5 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L17 ANSWER 1 OF 2 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 1
AN 2004:290378 BIOSIS
DN PREV200400292919
TI mAbs to Bacillus **anthracis** capsular antigen for immunoprotection in **anthrax** and detection of antigenemia.
AU Kozel, Thomas R. [Reprint Author]; Murphy, William J.; Brandt, Suzanne; Blazar, Bruce R.; **Lovchik, Julie A.**; Thorkildson, Peter; Percival, Ann; Lyons, C. Rick
CS Sch MedDept Microbiol and Immunol, Univ Nevada, Reno, NV, 89557, USA trkozel@med.unr.edu
SO Proceedings of the National Academy of Sciences of the United States of America, (April 6 2004) Vol. 101, No. 14, pp. 5042-5047. print.
ISSN: 0027-8424 (ISSN print).
DT Article
LA English
ED Entered STN: 23 Jun 2004
Last Updated on STN: 23 Jun 2004
AB Bacillus **anthracis** is surrounded by an antiphagocytic polypeptide capsule composed Of Poly gamma-D-glutamic acid (gammaDPGA). gammaDPGA has been identified recently as a potential target for vaccine development. Studies of the role of gammaDPGA in disease have been hampered by the poor Ab response to this antigen and the lack of immunochemical reagents. As a consequence, neither the extent of gammaDPGA production during **anthrax** nor the protective activity of gammaDPGA Abs in inhalation **anthrax** are known. Here we report production of IgG Abs to gammaDPGA in mice following an immunization regimen using gammaDPGA in combination with agonist mAbs to CD40. mAbs were produced that are specific for gammaDPGA. Passive immunization with gammaDPGA mAbs protected > 90% of mice in a pulmonary model of **anthrax** that was lethal in control mice ($P < 0.0001$). Use of gammaDPGA mAb in an antigen detection immunoassay found that the appearance of gammaDPGA in serum coincided with the emergence of bacteremia. These studies identify CD40 stimulation as a means for production of Ab and generation of mAbs against a weakly immunogenic antigen and demonstrate that the capsule is an effective target for immunoprotection and for antigen detection in the diagnosis of **anthrax**.

L17 ANSWER 2 OF 2 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 2
AN 2004:389933 BIOSIS
DN PREV200400392491
TI Murine model of pulmonary **anthrax**: Kinetics of dissemination, histopathology, and mouse strain susceptibility.
AU Lyons, C. Rick [Reprint Author]; **Lovchik, Julie**; Hutt, Julie; Lipscomb, Mary F.; Wang, Eugenia; Heninger, Sara; Berliba, Lucy; Garrison, Kristin
CS Hlth Sci CtrDept Internal MedInfect Dis and Inflammat Program, Univ New Mexico, M-S-C10 5550, Albuquerque, NM, 87131, USA clyons@salud.unm.edu
SO Infection and Immunity, (August 2004) Vol. 72, No. 8, pp. 4801-4809. print.
ISSN: 0019-9567 (ISSN print).
DT Article
LA English
ED Entered STN: 6 Oct 2004
Last Updated on STN: 6 Oct 2004
AB Bioweapons are most often designed for delivery to the lung, although this route is not the usual portal of entry for many of the pathogens in the natural environment. Vaccines and therapeutics that are efficacious for natural routes of infection may not be effective against the pulmonary

route. Pulmonary models are needed to investigate the importance of specific bacterial genes in virulence, to identify components of the host immune system that are important in providing innate and acquired protection, and for testing diagnostic and therapeutic strategies. This report describes the characteristics of host and Bacillus **anthracis** interactions in a murine pulmonary-infection model. The infective dose varied depending on the route and method of inoculation. The germination process in the lung began within 1 h of inoculation into the lung, although growth within the lung was limited. B. **anthracis** was found in the lung-associated lymph nodes apprx5 h after infection. Minimal pneumonitis was associated with the lung infection, but significant systemic pathology was noted after dissemination. Infected mice typically succumbed to infection apprx3 to 4 days after inoculation. The 50% lethal doses differed among inbred strains of mice, but within a given mouse strain, neither the age nor the sex of the mice influenced susceptibility to B. **anthracis**.

```
=> e lyons c rick/au
E1          212     LYONS C R/AU
E2           28     LYONS C RICHARD/AU
E3           24 --> LYONS C RICK/AU
E4           25     LYONS C S/AU
E5            1     LYONS C V/AU
E6           22     LYONS C W/AU
E7            9     LYONS C Y/AU
E8            1     LYONS CALVIN C/AU
E9            9     LYONS CALVIN G/AU
E10           2     LYONS CALVIN G JR/AU
E11           1     LYONS CALVIN R/AU
E12           3     LYONS CAREY/AU

=> s e1-e3 and (anthrac? or anthrax)
L18          23 ("LYONS C R"/AU OR "LYONS C RICHARD"/AU OR "LYONS C RICK"/AU)
                AND (ANTHRAC? OR ANTHRAX)

=> dup rem l18
PROCESSING COMPLETED FOR L18
L19            4 DUP REM L18 (19 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y


L19  ANSWER 1 OF 4  BIOSIS  COPYRIGHT (c) 2005 The Thomson Corporation  on STN
     DUPLICATE 1
AN   2005:173441  BIOSIS
DN   PREV200500172826
TI   Capsule synthesis by Bacillus anthracis is required for
     dissemination in murine inhalation anthrax.
AU   Drysdale, Melissa; Heninger, Sara; Hutt, Julie; Chen, Yahua; Lyons,
     C. Rick; Koehler, Theresa M. [Reprint Author]
CS   Houston Hlth Sci CtrSch MedDept Microbiol and Mol Genet, Univ Texas, 6431
     FAnnin St,JFB 1-765, Houston, TX, 77030, USA
     Theresa.M.Koehler@uth.tmc.edu
SO   EMBO (European Molecular Biology Organization) Journal, (January 12 2005)
     Vol. 24, No. 1, pp. 221-227. print.
     ISSN: 0261-4189 (ISSN print).
DT   Article
LA   English
ED   Entered STN: 4 May 2005
     Last Updated on STN: 4 May 2005
AB   Bacillus anthracis, the agent of anthrax, produces a
     poly- D-glutamic acid capsule that has been implicated in virulence. Many
     strains missing pXO2 ( 96 kb), which harbors the capsule biosynthetic
     operon capBCAD, but carrying pXO1 ( 182 kb) that harbors the
     anthrax toxin genes, are attenuated in animal models. Also,
     noncapsulated strains are readily phagocytosed by macrophage cell lines,
     whereas capsulated strains are resistant to phagocytosis. We show that a
```

strain carrying both virulence plasmids but deleted specifically for capBCAD is highly attenuated in a mouse model for inhalation **anthrax**. The parent strain and capsule mutant initiated germination in the lungs, but the capsule mutant did not disseminate to the spleen. A mutant harboring capBCAD but deleted for the cap regulators acpA and acpB was also significantly attenuated, in agreement with the capsule- negative phenotype during in vitro growth. Surprisingly, an acpB mutant, but not an acpA mutant, displayed an elevated LD50 and reduced ability to disseminate, indicating that acpA and acpB are not true functional homologs and that acpB may play a larger role in virulence than originally suspected.

L19 ANSWER 2 OF 4 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 2
AN 2004:290378 BIOSIS
DN PREV200400292919
TI mAbs to Bacillus **anthracis** capsular antigen for immunoprotection in **anthrax** and detection of antigenemia.
AU Kozel, Thomas R. [Reprint Author]; Murphy, William J.; Brandt, Suzanne; Blazar, Bruce R.; Lovchik, Julie A.; Thorkildson, Peter; Percival, Ann; **Lyons, C. Rick**
CS Sch MedDept Microbiol and Immunol, Univ Nevada, Reno, NV, 89557, USA
trkozel@med.unr.edu
SO Proceedings of the National Academy of Sciences of the United States of America, (April 6 2004) Vol. 101, No. 14, pp. 5042-5047. print.
ISSN: 0027-8424 (ISSN print).
DT Article
LA English
ED Entered STN: 23 Jun 2004
Last Updated on STN: 23 Jun 2004
AB Bacillus **anthracis** is surrounded by an antiphagocytic polypeptide capsule composed Of Poly gamma-D-glutamic acid (gammaDPGA). gammaDPGA has been identified recently as a potential target for vaccine development. Studies of the role of gammaDPGA in disease have been hampered by the poor Ab response to this antigen and the lack of immunochemical reagents. As a consequence, neither the extent of gammaDPGA production during **anthrax** nor the protective activity of gammaDPGA Abs in inhalation **anthrax** are known. Here we report production of IgG Abs to gammaDPGA in mice following an immunization regimen using gammaDPGA in combination with agonist mAbs to CD40. mAbs were produced that are specific for gammaDPGA. Passive immunization with gammaDPGA mAbs protected > 90% of mice in a pulmonary model of **anthrax** that was lethal in control mice ($P < 0.0001$). Use of gammaDPGA mAb in an antigen detection immunoassay found that the appearance of gammaDPGA in serum coincided with the emergence of bacteremia. These studies identify CD40 stimulation as a means for production of Ab and generation of mAbs against a weakly immunogenic antigen and demonstrate that the capsule is an effective target for immunoprotection and for antigen detection in the diagnosis of **anthrax**.

L19 ANSWER 3 OF 4 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 3
AN 2004:389933 BIOSIS
DN PREV200400392491
TI Murine model of pulmonary **anthrax**: Kinetics of dissemination, histopathology, and mouse strain susceptibility.
AU **Lyons, C. Rick** [Reprint Author]; Lovchik, Julie; Hutt, Julie; Lipscomb, Mary F.; Wang, Eugenia; Heninger, Sara; Berliba, Lucy; Garrison, Kristin
CS Hlth Sci CtrDept Internal MedInfect Dis and Inflammat Program, Univ New Mexico, M-S-C10 5550, Albuquerque, NM, 87131, USA
clyons@salud.unm.edu
SO Infection and Immunity, (August 2004) Vol. 72, No. 8, pp. 4801-4809. print.
ISSN: 0019-9567 (ISSN print).
DT Article
LA English
ED Entered STN: 6 Oct 2004

Last Updated on STN: 6 Oct 2004

AB Bioweapons are most often designed for delivery to the lung, although this route is not the usual portal of entry for many of the pathogens in the natural environment. Vaccines and therapeutics that are efficacious for natural routes of infection may not be effective against the pulmonary route. Pulmonary models are needed to investigate the importance of specific bacterial genes in virulence, to identify components of the host immune system that are important in providing innate and acquired protection, and for testing diagnostic and therapeutic strategies. This report describes the characteristics of host and Bacillus **anthracis** interactions in a murine pulmonary-infection model. The infective dose varied depending on the route and method of inoculation. The germination process in the lung began within 1 h of inoculation into the lung, although growth within the lung was limited. B. **anthracis** was found in the lung-associated lymph nodes apprx5 h after infection. Minimal pneumonitis was associated with the lung infection, but significant systemic pathology was noted after dissemination. Infected mice typically succumbed to infection apprx3 to 4 days after inoculation. The 50% lethal doses differed among inbred strains of mice, but within a given mouse strain, neither the age nor the sex of the mice influenced susceptibility to B. **anthracis**.

L19 ANSWER 4 OF 4 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 4

AN 2005:35763 BIOSIS

DN PREV200500038660

TI Organism identification using a genome sequence-independent universal microarray probe set.

AU Belosludtsev, Yuri Y.; Bowerman, Dawn; Weil, Ryan; Marthandan, Nishanth; Balog, Robert; Luebke, Kevin; Lawson, Jonathan; Johnston, Stephen A.; **Lyons, C. Rick**; O'Brien, Kevin; Garner, Harold R. [Reprint Author]; Powdrill, Thomas F.

CS UT Southwestern Med Ctr, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA garner@swmed.edu

SO BioTechniques, (October 2004) Vol. 37, No. 4, pp. 654-658, 660. print. ISSN: 0736-6205 (ISSN print).

DT Article

LA English

ED Entered STN: 19 Jan 2005
Last Updated on STN: 19 Jan 2005

AB There has been increasing interest and efforts devoted to developing biosensor technologies for identifying pathogens, particularly in the biothreat area. In this study, a universal set of short 12- and 13-mer oligonucleotide probes was derived independently of a priori genomic sequence information and used to generate unique species-dependent genomic hybridization signatures. The probe set sequences were algorithmically generated to be maximally distant in sequence space and not dependent on the sequence of any particular genome. The probe set is universally applicable because it is unbiased and independent of hybridization predictions based upon simplified assumptions regarding probe-target duplex formation from linear sequence analysis. Tests were conducted on microarrays containing 14,283 unique probes synthesized using in in situ light-directed synthesis methodology. The genomic DNA hybridization intensity patterns reproducibly differentiated various organisms (Bacillus subtilis, Yersinia pestis, Streptococcus pneumonia, Bacillus **anthracis**, and Homo sapiens), including the correct identification of a blinded "unknown" sample. Applications of this method include not only pathological and forensic genome identification in medicine and basic science, but also potentially a novel method for the discovery of unknown targets and associations inherent in dynamic nucleic acid populations such as represented by differential gene expression.

=> s antibod? and (polyglutamic acid)
L20 2067 ANTIBOD? AND (POLYGLUTAMIC ACID)

=> s l20 and (anthrac? or anthrax)
L21 207 L20 AND (ANTHRAC? OR ANTHRAX)

```
=> dup rem l21
PROCESSING COMPLETED FOR L21
L22         206 DUP REM L21 (1 DUPLICATE REMOVED)

=> s l22 and immunoassay?
L23          77 L22 AND IMMUNOASSAY?

=> s l23 and (anthrac?/ti or anthrax/ab)
'AB' IS NOT A VALID FIELD CODE
'AB' IS NOT A VALID FIELD CODE
'AB' IS NOT A VALID FIELD CODE
L24           4 L23 AND (ANTHRAC?/TI OR ANTHRAX/AB)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L24  ANSWER 1 OF 4  EMBASE  COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.
     on STN
AN   2004163147  EMBASE
TI   mAbs to Bacillus anthracis capsular antigen for immunoprotection
     in anthrax and detection of antigenemia.
AU   Kozel T.R.; Murphy W.J.; Brandt S.; Blazar B.R.; Lovchik J.A.; Thorkildson
     P.; Percival A.; Lyons C.R.
CS   T.R. Kozel, Dept. of Microbiology and Immunology, Univ. of Nevada School
     of Medicine, Reno, NV 89557, United States. trkozel@med.unr.edu
SO   Proceedings of the National Academy of Sciences of the United States of
     America, (6 Apr 2004) Vol. 101, No. 14, pp. 5042-5047.
     Refs: 21
     ISSN: 0027-8424  CODEN: PNASA6
CY   United States
DT   Journal; Article
FS   004     Microbiology
     037     Drug Literature Index
LA   English
SL   English
ED   Entered STN: 20040528
     Last Updated on STN: 20040528
AB   Bacillus anthracis is surrounded by an antiphagocytic
     polypeptide capsule composed of poly γ-D-glutamic acid
     (γDPGA). γDPGA has been identified recently as a potential
     target for vaccine development. Studies of the role of γDPGA in
     disease have been hampered by the poor Ab response to this antigen and the
     lack of immunochemical reagents. As a consequence, neither the extent of
     γDPGA production during anthrax nor the protective
     activity of γDPGA Abs in inhalation anthrax are known.
     Here we report production of IgG Abs to γDPGA in mice following an
     immunization regimen using γDPGA in combination with agonist mAbs to
     CD40. mAbs were produced that are specific for γDPGA. Passive
     immunization with γDPGA mAbs protected >90% of mice in a pulmonary
     model of anthrax that was lethal in control mice (P < 0.0001).
     Use of γDPGA mAb in an antigen detection immunoassay found
     that the appearance of γDPGA in serum coincided with the emergence
     of bacteremia. These studies identify CD40 stimulation as a means for
     production of Ab and generation of mAbs against a weakly immunogenic
     antigen and demonstrate that the capsule is an effective target for
     immunoprotection and for antigen detection in the diagnosis of
     anthrax.

L24  ANSWER 2 OF 4  USPATFULL on STN
AN     2005:143741  USPATFULL
TI     Imaging the activity of extracellular protease in cells using mutant
       anthrax toxin protective antigens that are cleaved by specific
       extracellular proteases
IN     Bugge, Thomas H., Bethesda, MD, UNITED STATES
       Leppla, Stephen H., Bethesda, MD, UNITED STATES
       Liu, Shi-Hui, Rockville, MD, UNITED STATES
       Mitola, David, Baltimore, MD, UNITED STATES
PA     The Government of the United States as represented by the Secretary of
       the Department of Health and, Rockville, MD, UNITED STATES, 20852-3804
```

(U.S. corporation)
PI US 2005123476 A1 20050609
AI US 2003-488806 A1 20020905 (10)
WO 2002-US28397 20020905
PRAI US 2003-317550P 20010905 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, 8TH FLOOR, SAN FRANCISCO, CA, 94111, US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4268
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention pertains to methods for imaging the activity of extracellular proteases in cells using the **anthrax** binary toxin-system to target cells expressing extracellular proteases with mutant **anthrax** toxin protective antigens (μPrAg) that bind to receptors on the cells and are cleaved by a specific extracellular protease expressed by the cells, and ligands that specifically bind to the cleaved μPrAg and are linked to a moiety that is detectable by an imaging procedure. The μPrAg proteins used in the methods comprise a protease cleavage site that is cleaved by a specific extracellular protease and is in place of the furin cleavage site of the native PrAg. The methods are useful for diagnosing and treating diseases and undesirable physiological conditions correlated with the activity of extracellular proteases, and for optimizing the therapeutic efficacy of drugs used to treat such diseases and conditions.

L24 ANSWER 3 OF 4 USPATFULL on STN
AN 2004:221352 USPATFULL
TI Methods for preparing Bacillus **anthracis** sporulation deficient mutants and for producing recombinant Bacillus **anthracis** protective antigen for use in vaccines
IN Leppla, Stephen H., Bethesda, MD, UNITED STATES
Rosovitz, Mary Jo, Kensington, MD, UNITED STATES
Hsu, S. Dana, Bethesda, MD, UNITED STATES
PI US 2004171121 A1 20040902
AI US 2003-638006 A1 20030808 (10)
PRAI US 2002-402285P 20020809 (60)
DT Utility
FS APPLICATION
LREP KLARQUIST SPARKMAN, LLP, 121 S.W. SALMON STREET, SUITE #1600, ONE WORLD TRADE CENTER, PORTLAND, OR, 97204-2988
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1786
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to improved methods of producing and recovering sporulation-deficient B. **anthracis** mutant stains, and for producing and recovering recombinant B. **anthracis** protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. **anthracis** bacterial infections and which are useful to prevent and/or treat illnesses caused by B. **anthracis**, such as inhalation **anthrax**, cutaneous **anthrax** and gastrointestinal **anthrax**.

L24 ANSWER 4 OF 4 USPATFULL on STN
AN 2004:100777 USPATFULL
TI Methods for preparing bacillus **anthracis** protective antigen for use in vaccines
IN Shiloach, Joseph, Rockville, MD, UNITED STATES
Leppla, Stephen H., Bethesda, MD, UNITED STATES
Ramirez, Delia M., Bethesda, MD, UNITED STATES
Schneerson, Rachel, Bethesda, MD, UNITED STATES

Robbins, John B., Chevy Chase, MD, UNITED STATES
PI US 2004076638 A1 20040422
AI US 2002-290712 A1 20021108 (10)
PRAI US 2001-344505P 20011109 (60)
DT Utility
FS APPLICATION
LREP KLARQUIST SPARKMAN, LLP, 121 S.W. SALMON STREET, SUITE #1600, ONE WORLD TRADE CENTER, PORTLAND, OR, 97204-2988
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1273
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to improved methods of producing and recovering B. **anthracisprotective** antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. **anthracis** bacterial infections and which are useful to prevent and/or treat illnesses caused by B. **anthracis**, such as inhalation **anthrax**, cutaneous **anthrax** and gastrointestinal **anthrax**.

=> s l23 and (polyglutamic/ti or polyglutamic/ab)
'AB' IS NOT A VALID FIELD CODE
'AB' IS NOT A VALID FIELD CODE
'AB' IS NOT A VALID FIELD CODE
L25 0 L23 AND (POLYGLUTAMIC/TI OR POLYGLUTAMIC/AB)

=> s l23 and pga
L26 5 L23 AND PGA

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L26 ANSWER 1 OF 5 USPATFULL on STN
AN 2005:125479 USPATFULL
TI Medical device with multiple coating layers
IN Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard J., Rochester, NY, UNITED STATES
PI US 2005107870 A1 20050519
AI US 2004-923579 A1 20040820 (10)
RLI Continuation-in-part of Ser. No. US 2004-914691, filed on 9 Aug 2004, PENDING Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, GRANTED, Pat. No. US 6846985 Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609
DT Utility
FS APPLICATION
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408, US
CLMN Number of Claims: 62
ECL Exemplary Claim: 1
DRWN 54 Drawing Page(s)
LN.CNT 18628
AB An implantable medical device that contains two coating layers disposed above at least one of its surfaces. The first coating layer contains a biologically active material; and the second coating layer contains a polymeric material and nanomagnetic material disposed on the first

coating layer; the second coating layer is substantially free of the biologically active material. The nanomagentic material has a saturation magentization of from about 2 to about 3000 electromagnetic units per cubic centimeter, and it contains nanomagnetic particleswith an average particle size of less than about 100 nanometers; the average coherence length between adjacent nanomagnetic particles is less than 100 nanometers.

L26 ANSWER 2 OF 5 USPATFULL on STN
AN 2005:92457 USPATFULL
TI Medical device with low magnetic susceptibility
IN Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard J., Rochester, NY, UNITED STATES
Gunderman, Robert D., Honeyoye Falls, NY, UNITED STATES
PI US 2005079132 A1 20050414
AI US 2004-914691 A1 20040809 (10)
RLI Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, GRANTED, Pat. No. US 6846985 Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609
DT Utility
FS APPLICATION
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408, US
CLMN Number of Claims: 127
ECL Exemplary Claim: 1
DRWN 52 Drawing Page(s)
LN.CNT 17912
AB An assembly with a substrate, nanomagnetic material and magetoresistive material. The nanomagnetic material has a saturation magentization of from about 2 to about 3000 electromagnetic units per cubic centimeter; and it contains nanomagnetic particles with an average particle size of less than about 100 nanometers. The average coherence length between adjacent nanomagnetic particles is less than 100 nanometers.

L26 ANSWER 3 OF 5 USPATFULL on STN
AN 2005:30367 USPATFULL
TI Medical device with low magnetic susceptibility
IN Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard Jay, Rochester, NY, UNITED STATES
PI US 2005025797 A1 20050203
AI US 2004-887521 A1 20040707 (10)
RLI Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609
DT Utility
FS APPLICATION
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408
CLMN Number of Claims: 137
ECL Exemplary Claim: 1
DRWN 42 Drawing Page(s)
LN.CNT 17461

AB An assembly that contains a medical device and biological material within which the medical device is disposed. The assembly has a magnetic susceptibility within the range of plus or minus 1+10.sup.-3 centimeter-gram-seconds

L26 ANSWER 4 OF 5 USPATFULL on STN
AN 2004:321764 USPATFULL
TI Therapeutic assembly
IN Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard J., Rochester, NY, UNITED STATES
Lanzafame, John, Victor, NY, UNITED STATES
Weiner, Michael L., Webster, NY, UNITED STATES
Connelly, Patrick R., Rochester, NY, UNITED STATES
PI US 2004254419 A1 20041216
AI US 2004-867517 A1 20040614 (10)
RLI Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING
DT Utility
FS APPLICATION
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408
CLMN Number of Claims: 175
ECL Exemplary Claim: CLM-1-177
DRWN 40 Drawing Page(s)
LN.CNT 16208
AB A therapeutic assembly that contains a therapeutic agent, a ctyotoxic radioactive material, and a nanomagnetic material with nanomagnetic particles. The nanomagentic particles have an average particle size of less than about 100 nanometers; and the average coherence length between adjacent nanomagnetic particles is less than 100 nanometers. The nanomagnetic material has a saturation magentization of from about 2 to about 3000 electromagnetic units per cubic centimeter, a phase transition temperature of from about 40 to about 200 degrees Celsius, and a saturation magnetization of from about 2 to about 3,000 electromagnetic units per cubic centimeter

L26 ANSWER 5 OF 5 USPATFULL on STN
AN 2003:264856 USPATFULL
TI Interfacial biomaterials
IN Grinstaff, Mark W., Durham, NC, UNITED STATES
Kenan, Daniel J., Chapel Hill, NC, UNITED STATES
Walsh, Elisabeth B., Durham, NC, UNITED STATES
Middleton, Crystan, Arlington, VA, UNITED STATES
PI US 2003185870 A1 20031002
AI US 2002-300694 A1 20021120 (10)
PRAI US 2001-331843P 20011120 (60)
DT Utility
FS APPLICATION
LREP JENKINS & WILSON, PA, 3100 TOWER BLVD, SUITE 1400, DURHAM, NC, 27707
CLMN Number of Claims: 229
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4272
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An interfacial biomaterial prepared using a plurality of binding agents, each binding agent including a first ligand that specifically binds a non-biological substrate and a second ligand that specifically binds a biological substrate. Also provided is an interfacial biomaterial prepared using a plurality of binding agents, each binding agent including a ligand that specifically binds a non-biological substrate and a non-binding domain that shows substantially no binding to a

biological substrate. Also provided are methods for preparing a binding agent, methods for preparing an interfacial biomaterial, and methods for using interfacial biomaterials.

=> s l23 and anti-pga
L27 0 L23 AND ANTI-PGA

=> d bib ab l23 1-
YOU HAVE REQUESTED DATA FROM 77 ANSWERS - CONTINUE? Y/(N):y

L23 ANSWER 1 OF 77 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004163147 EMBASE
TI mAbs to Bacillus **anthracis** capsular antigen for immunoprotection in **anthrax** and detection of antigenemia.
AU Kozel T.R.; Murphy W.J.; Brandt S.; Blazar B.R.; Lovchik J.A.; Thorkildson P.; Percival A.; Lyons C.R.
CS T.R. Kozel, Dept. of Microbiology and Immunology, Univ. of Nevada School of Medicine, Reno, NV 89557, United States. trkozel@med.unr.edu
SO Proceedings of the National Academy of Sciences of the United States of America, (6 Apr 2004) Vol. 101, No. 14, pp. 5042-5047.
Refs: 21
ISSN: 0027-8424 CODEN: PNASA6
CY United States
DT Journal; Article
FS 004 Microbiology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 20040528
Last Updated on STN: 20040528
AB Bacillus **anthracis** is surrounded by an antiphagocytic polypeptide capsule composed of poly γ-D-glutamic acid (γDPGA). γDPGA has been identified recently as a potential target for vaccine development. Studies of the role of γDPGA in disease have been hampered by the poor Ab response to this antigen and the lack of immunochemical reagents. As a consequence, neither the extent of γDPGA production during **anthrax** nor the protective activity of γDPGA Abs in inhalation **anthrax** are known. Here we report production of IgG Abs to γDPGA in mice following an immunization regimen using γDPGA in combination with agonist mAbs to CD40. mAbs were produced that are specific for γDPGA. Passive immunization with γDPGA mAbs protected >90% of mice in a pulmonary model of **anthrax** that was lethal in control mice ($P < 0.0001$). Use of γDPGA mAb in an antigen detection **immunoassay** found that the appearance of γDPGA in serum coincided with the emergence of bacteremia. These studies identify CD40 stimulation as a means for production of Ab and generation of mAbs against a weakly immunogenic antigen and demonstrate that the capsule is an effective target for immunoprotection and for antigen detection in the diagnosis of **anthrax**.

L23 ANSWER 2 OF 77 USPATFULL on STN
AN 2005:196220 USPATFULL
TI Reduction of migration shift assay interference
IN Wada, H. Garrett, Atherton, CA, UNITED STATES
Kazakova, Irina G., Los Gatos, CA, UNITED STATES
Yutaka, Miki, Takarazuka, JAPAN
Ohashi, Toshinari, Amagasaki, JAPAN
Kanke, Futoshi, Midlothian, VA, UNITED STATES
PA Caliper Life Sciences, Inc., Hopkinton, MA, UNITED STATES (non-U.S. corporation)
Wako Pure Chemical Industries, Ltd., Tokyo, JAPAN (non-U.S. corporation)
PI US 2005170362 A1 20050804
AI US 2004-821657 A1 20040408 (10)
PRAI US 2003-462636P 20030414 (60)
US 2003-500177P 20030904 (60)
DT Utility

FS APPLICATION
LREP CALIPER LIFE SCIENCES, INC., 605 FAIRCHILD DRIVE, MOUNTAIN VIEW, CA, 94043-2234, US
CLMN Number of Claims: 93
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 4385
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides methods and compositions, e.g., to reduce interference from non-specific binding sample constituents in a migration shift assay. Interference due to non-specific binding of sample constituents to an affinity substance (e.g., an affinity molecule or a conjugate of an affinity molecule and a charged carrier molecule) is prevented by, e.g., binding the constituents to charged polymers such as heparin sulfate. The present invention also provides methods to concentrate an analyte of interest with high concentration and to detect the analyte with high sensitivity, and further to optimize the reaction conditions for easily concentrating the analyte. Such objects of the present invention are attained, for example, by concentrating a complex of the analyte and a conjugate which is formed by contacting the analyte in a sample with an affinity molecule bound to a charged carrier molecule such as DNA.

L23 ANSWER 3 OF 77 USPATFULL on STN
AN 2005:189291 USPATFULL
TI Materials and methods relating to therapy and diagnosis using targeting of cells that express JPL polypeptides
IN Emtage, Peter C. R., Sunnyvale, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Zhao, Qing A., San Jose, CA, UNITED STATES
Liu, Chenghua, San Jose, CA, UNITED STATES
Drmanac, Radoje T., Los Altos Hills, CA, UNITED STATES
PI US 2005164202 A1 20050728
AI US 2003-627373 A1 20030724 (10)
RLI Continuation-in-part of Ser. No. US 2002-293244, filed on 12 Nov 2002, PENDING Continuation-in-part of Ser. No. US 258899, ABANDONED A 371 of International Ser. No. WO 2001-US4098, filed on 5 Feb 2001 Continuation-in-part of Ser. No. US 2000-654936, filed on 1 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-560875, filed on 27 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-496914, filed on 3 Feb 2000, ABANDONED
DT Utility
FS APPLICATION
LREP NUVELO, INC, 675 ALMANOR AVE., SUNNYVALE, CA, 94085, US
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 7462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Certain cells, including types of cancer cells such as melanoma cells, are capable of expressing junctophilin-like (JPL) RNA. Targeting using JPL polypeptides, nucleic acids encoding for JPL polypeptides and anti-JPL **antibodies** provides a method of killing or inhibiting that growth of melanoma cancer cells that express the JPL protein. Targeting materials and methods for the diagnosis and therapy of melanomas that express JPL are described.

L23 ANSWER 4 OF 77 USPATFULL on STN
AN 2005:182941 USPATFULL
TI Methods of therapy and diagnosis using targeting of cells that express BCLP polypeptides
IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
PI US 2005158324 A1 20050721
AI US 2004-14487 A1 20041215 (11)
RLI Continuation-in-part of Ser. No. US 2003-737666, filed on 15 Dec 2003, PENDING
DT Utility
FS APPLICATION
LREP NUVELO, INC, 675 ALMANOR AVE., SUNNYVALE, CA, 94085, US

CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 3378
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Certain cells, including cancer cells such as cells from cancers of the colon, breast, lung, ovary, prostate, pancreas and skin are capable of expressing BCLP. Targeting using BCLP polypeptides, nucleic acids encoding for BCLP polypeptides, anti-BCLP **antibodies**, peptides and small molecules provides a method of killing or inhibiting the growth of the cancer cells that express the BCLP protein. Methods for the diagnosis and therapy of tumors that express BCLP are described.

L23 ANSWER 5 OF 77 USPATFULL on STN
AN 2005:165148 USPATFULL
TI Compositions, splice variants and methods relating to lung specific nucleic acids and proteins
IN Macina, Roberto A., San Jose, CA, UNITED STATES
Turner, Leah R., Sunnyvale, CA, UNITED STATES
Sun, Yongming, Redwood City, CA, UNITED STATES
PI US 2005142572 A1 20050630
AI US 2004-852707 A1 20040524 (10)
PRAI US 2003-473941P 20030522 (60)
DT Utility
FS APPLICATION
LREP Licata & Tyrrell P.C., 66 E. Main Street, Marlton, NJ, 08053, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 19148
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic lung cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to **antibodies** to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, **antibodies**, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating lung cancer and non-cancerous disease states in lung, identifying lung tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered lung tissue for treatment and research.

L23 ANSWER 6 OF 77 USPATFULL on STN
AN 2005:165115 USPATFULL
TI Targeted ligands
IN Herman, William, Thornhill, CANADA
PI US 2005142539 A1 20050630
AI US 2004-943918 A1 20040920 (10)
RLI Continuation-in-part of Ser. No. WO 2003-CA44, filed on 14 Jan 2003, UNKNOWN
PRAI CA 2002-2368708 20020114
CA 2002-2397169 20020813
CA 2002-2402930 20020919
CA 2002-2368708 20020114
US 2003-504283P 20030919 (60)
DT Utility
FS APPLICATION
LREP BERESKIN AND PARR, 40 KING STREET WEST, BOX 401, TORONTO, ON, M5H 3Y2, CA
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention contemplates a composition containing a multispecific ligand containing at least a first ligand binding moiety and a second ligand binding moiety. The first ligand binding moiety specifically binds with a pre-selected first affinity to at least a first ligand. The first ligand has a first biodistribution. The second ligand binding moiety specifically binds with a pre-selected affinity to at least a second ligand. The second ligand has a second biodistribution. The affinities of first and second ligand binding moieties are selected to bias the biodistribution of the multispecific ligand in favour of a selected location of one or both of the ligands.

L23 ANSWER 7 OF 77 USPATFULL on STN
AN 2005:158986 USPATFULL
TI Medical devices employing triazine compounds and compositions thereof
IN Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES
Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Yeleswarapu, Koteswar Rao, Begumpet, INDIA
Pal, Manojit, Miyapur, INDIA
Reddy, Jangalgar Tirupathy, Miyapur, INDIA
Krishna Reddy, Velagala Venkata Rama Murali, Kukatpally, INDIA
Sesha Sridevi, Bhatlapenumarthy, Gandhinagar, INDIA
Kumar, Potlapally Rajender, Miyapur, INDIA
Reddy, Gaddam Om, Miyapur, INDIA
PI US 2005137196 A1 20050623
AI US 2004-951316 A1 20040927 (10)
RLI Division of Ser. No. US 2003-397968, filed on 26 Mar 2003, PENDING Continuation-in-part of Ser. No. US 2003-390485, filed on 17 Mar 2003, PENDING Continuation of Ser. No. US 2002-253388, filed on 23 Sep 2002, ABANDONED
PRAI US 2001-324147P 20010921 (60)
DT Utility
FS APPLICATION
LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA, 30357-0037, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 86 Drawing Page(s)
LN.CNT 9874
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

L23 ANSWER 8 OF 77 USPATFULL on STN
AN 2005:151242 USPATFULL
TI Compositions and methods relating to endometrial specific genes and proteins
IN Sun, Yongming, Redwood City, CA, UNITED STATES
Liu, Chenghua, San Jose, CA, UNITED STATES
PI US 2005130154 A1 20050616
AI US 2003-499352 A1 20021223 (10)
WO 2002-US41612 20021223
PRAI US 2003-342756P 20011221 (60)
DT Utility
FS APPLICATION
LREP LICATA & TYRRELL P.C., 66 E. MAIN STREET, MARLTON, NJ, 08053, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 8303
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic endometrial cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to **antibodies** to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, **antibodies**, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating endometrial cancer and non-cancerous disease states in endometria, identifying endometrial tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered endometrial tissue for treatment and research.

L23 ANSWER 9 OF 77 USPATFULL on STN
AN 2005:150786 USPATFULL
TI Methods of therapy and diagnosis using targeting of cells that express BCLP polypeptides
IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
PI US 2005129697 A1 20050616
AI US 2003-737666 A1 20031215 (10)
DT Utility
FS APPLICATION
LREP NUVELO, INC, 675 ALMANOR AVE., SUNNYVALE, CA, 94085, US
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 3289
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Certain cells, including cancer cells such as cells from colon tumors, are capable of expressing BCLP RNA. Targeting using BCLP polypeptides, nucleic acids encoding for BCLP polypeptides, anti-BCLP **antibodies**, peptides and small molecules provides a method of killing or inhibiting the growth of colon cancer cells that express the BCLP protein. Methods for the diagnosis and therapy of colon tumors that express BCLP are described.

L23 ANSWER 10 OF 77 USPATFULL on STN
AN 2005:144879 USPATFULL
TI Medical devices employing triazine compounds and compositions thereof
IN Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES
Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Yeleswarapu, Koteswar Rao, Hyderabad, INDIA
Pal, Manojit, Hyderabad, INDIA
Reddy, Jangalgar Tirupathy, Hyderabad, INDIA
Krisha Reddy, Velagala Venkata Rama Murali, Hyderabad, INDIA
Sesha Sridevi, Bhatlapenumarthy, Hyderbad, INDIA
Kumar, Potlapally Rajender, Hyderabad, INDIA
Reddy, Gaddam Om, Hyderabad, INDIA
PI US 2005124619 A1 20050609
AI US 2004-951120 A1 20040927 (10)
RLI Division of Ser. No. US 2003-400169, filed on 26 Mar 2003, PENDING Continuation-in-part of Ser. No. US 2003-390485, filed on 17 Mar 2003, PENDING Continuation of Ser. No. US 2002-253388, filed on 23 Sep 2002, ABANDONED
PRAI US 2001-324147P 20010921 (60)
DT Utility
FS APPLICATION
LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA, 30357-0037, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1

DRWN 86 Drawing Page(s)
LN.CNT 8532
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

L23 ANSWER 11 OF 77 USPATFULL on STN
AN 2005:143816 USPATFULL
TI Compositions and methods relating to endometrial specific genes and proteins
IN Sun, Yongming, Redwood City, CA, UNITED STATES
Liu, Chenghua, San Jose, CA, UNITED STATES
PI US 2005123551 A1 20050609
AI US 2003-499353 A1 20021220 (10)
WO 2002-US41413 20021220
PRAI US 2003-342751P 20011221 (60)
DT Utility
FS APPLICATION
LREP LICATA & TYRRELL P.C., 66 E. MAIN STREET, MARLTON, NJ, 08053, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic endometrial cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to **antibodies** to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, **antibodies**, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating endometrial cancer and non-cancerous disease states in endometrial, identifying endometrial tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered endometrial tissue for treatment and research.

L23 ANSWER 12 OF 77 USPATFULL on STN
AN 2005:143741 USPATFULL
TI Imaging the activity of extracellular protease in cells using mutant **anthrax** toxin protective antigens that are cleaved by specific extracellular proteases
IN Bugge, Thomas H., Bethesda, MD, UNITED STATES
Leppla, Stephen H., Bethesda, MD, UNITED STATES
Liu, Shi-Hui, Rockville, MD, UNITED STATES
Mitola, David, Baltimore, MD, UNITED STATES
PA The Government of the United States as represented by the Secretary of the Department of Health and, Rockville, MD, UNITED STATES, 20852-3804 (U.S. corporation)
PI US 2005123476 A1 20050609
AI US 2003-488806 A1 20020905 (10)
WO 2002-US28397 20020905
PRAI US 2003-317550P 20010905 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, 8TH FLOOR,

SAN FRANCISCO, CA, 94111, US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4268
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention pertains to methods for imaging the activity of extracellular proteases in cells using the **anthrax** binary toxin-system to target cells expressing extracellular proteases with mutant **anthrax** toxin protective antigens (μPrAg) that bind to receptors on the cells and are cleaved by a specific extracellular protease expressed by the cells, and ligands that specifically bind to the cleaved μPrAg and are linked to a moiety that is detectable by an imaging procedure. The μPrAg proteins used in the methods comprise a protease cleavage site that is cleaved by a specific extracellular protease and is in place of the furin cleavage site of the native PrAg. The methods are useful for diagnosing and treating diseases and undesirable physiological conditions correlated with the activity of extracellular proteases, and for optimizing the therapeutic efficacy of drugs used to treat such diseases and conditions.

L23 ANSWER 13 OF 77 USPATFULL on STN
AN 2005:138619 USPATFULL
TI Heterocyclic compounds and methods of making and using thereof
IN Rao, Yeleswarapu Koteswar, Hyderabad, INDIA
Pal, Manojit, Hyderabad, INDIA
Sharma, Vedula Manohar, Hyderabad, INDIA
Venkateswarlu, Akella, Hyderabad, INDIA
Pillarisetti, Ram, Norcross, GA, UNITED STATES
PI US 2005119269 A1 20050602
AI US 2004-976284 A1 20041028 (10)
PRAI IN 2003-8612003 20031028
US 2004-610163P 20040915 (60)
DT Utility
FS APPLICATION
LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA, 30357-0037, US
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 13564
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I), and methods and/or compositions comprising compounds that are effective in modulating inflammatory responses, such as those resulting from AGE and glycated protein accumulation are provided. Methods and/or compositions comprising compounds that are effective in modulating smooth muscle cell proliferation and the diseases or conditions related thereto are also provided. ##STR1##

L23 ANSWER 14 OF 77 USPATFULL on STN
AN 2005:137555 USPATFULL
TI Process for covalently conjugating polysaccharides to microspheres or biomolecules
IN Esser, Mark T., Collegeville, PA, UNITED STATES
Schlottmann, Sonela A., Newbury Park, CA, UNITED STATES
PI US 2005118199 A1 20050602
AI US 2004-960522 A1 20041007 (10)
PRAI US 2003-509189P 20031007 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ, 07065-0907, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1179
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to novel processes for covalently conjugating polysaccharides to microspheres or other biomolecules, and more specifically to the use of 4-(4,6-

dimethoxy[1,3,5]triazin-2-yl)-4-methyl-morpholinium chloride (DMTMM) in said processes

L23 ANSWER 15 OF 77 USPATFULL on STN
AN 2005:137520 USPATFULL
TI Targeted ligands
IN Herman, William, Thornhill, CANADA
PI US 2005118164 A1 20050602
AI US 2003-481670 A1 20020311 (10)
WO 2002-CA317 20020311
PRAI CA 2003-2368708 20020114
US 2003-274217P 20010309 (60)
US 2003-276911P 20010320 (60)
US 2003-279132P 20010328 (60)
US 2003-281029P 20010404 (60)
US 2003-306148P 20010719 (60)
DT Utility
FS APPLICATION
LREP BERESKIN AND PARR, 40 KING STREET WEST, BOX 401, TORONTO, ON, M5H 3Y2, CA
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7721
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention contemplates a composition containing a multispecific ligand containing at least a first ligand binding moiety and a second ligand binding moiety. The first ligand binding moiety specifically binds with a pre-selected first affinity to at least a first ligand. The first ligand has a first biodistribution. The second ligand binding moiety specifically binds with a pre-selected affinity to at least a second ligand. The second ligand has a second biodistribution. The affinity of first and second ligand binding moieties arc selected to bias the biodistribution of the multispecific ligand in favour of a selected location of one or both of the ligands.

L23 ANSWER 16 OF 77 USPATFULL on STN
AN 2005:131877 USPATFULL
TI Medical devices employing triazine compounds and compositions thereof
IN Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES
Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Yeleswarapu, Koteswar Rao, Hyderabad, IN, UNITED STATES
Pal, Manojit, Hyderabad, INDIA
Reddy, Jangalgar Tirupathy, Hyderabad, INDIA
Murali Krishna Reddy, Velagala Venkata Rama, Hyderabad, INDIA
Sridevi, Bhatlapenumarthy Sesha, Hyderabad, INDIA
Kumar, Potlapally Rajender, Hyderabad, INDIA
Reddy, Gaddam Om, Hyderabad, INDIA
PI US 2005113341 A1 20050526
AI US 2004-951305 A1 20040927 (10)
RLI Division of Ser. No. US 2003-400134, filed on 26 Mar 2003, PENDING Continuation-in-part of Ser. No. US 2003-390485, filed on 17 Mar 2003, PENDING Continuation of Ser. No. US 2002-253388, filed on 23 Sep 2002, ABANDONED
PRAI US 2001-324147P 20010921 (60)
DT Utility
FS APPLICATION
LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA, 30357-0037, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 86 Drawing Page(s)
LN.CNT 10723
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed

to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

L23 ANSWER 17 OF 77 USPATFULL on STN
AN 2005:131832 USPATFULL
TI Methods for identifying antimicrobial agents, the agents identified therewith and methods of using same
IN Pollard, Mike G., Alameda, CA, UNITED STATES
Cota, Adam, Berkeley, CA, UNITED STATES
Hoeppner, Corey, Dublin, CA, UNITED STATES
Mehlhorn, Ingrid E., San Francisco, CA, UNITED STATES
Cole, Timothy David, Concord, CA, UNITED STATES
Neiman, Joshua Alan, Albany, CA, UNITED STATES
Roberts, T. Guy, Oakland, CA, UNITED STATES
Mitchell, Wayne, San Francisco, CA, UNITED STATES
PI US 2005113296 A1 20050526
AI US 2003-606406 A1 20030625 (10)
RLI Continuation-in-part of Ser. No. US 2002-183923, filed on 25 Jun 2002, ABANDONED Continuation-in-part of Ser. No. US 2002-184503, filed on 26 Jun 2002, PENDING
PRAI US 2001-301274P 20010626 (60)
US 2002-396535P 20020715 (60)
DT Utility
FS APPLICATION
LREP QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 2040
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods of identifying compounds that inhibit specific tRNA:34A deaminases encoded by yfhC genes, compounds that inhibit such deaminases and methods of using the deaminases in a variety of in vitro and in vivo contexts, such as in the treatment and prevention of bacterial infections.

L23 ANSWER 18 OF 77 USPATFULL on STN
AN 2005:125479 USPATFULL
TI Medical device with multiple coating layers
IN Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard J., Rochester, NY, UNITED STATES
PI US 2005107870 A1 20050519
AI US 2004-923579 A1 20040820 (10)
RLI Continuation-in-part of Ser. No. US 2004-914691, filed on 9 Aug 2004, PENDING Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, GRANTED, Pat. No. US 6846985 Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609
DT Utility
FS APPLICATION
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408, US
CLMN Number of Claims: 62
ECL Exemplary Claim: 1

DRWN 54 Drawing Page(s)
LN.CNT 18628
AB An implantable medical device that contains two coating layers disposed above at least one of its surfaces. The first coating layer contains a biologically active material; and the second coating layer contains a polymeric material and nanomagnetic material disposed on the first coating layer; the second coating layer is substantially free of the biologically active material. The nanomagentic material has a saturation magentization of from about 2 to about 3000 electromagnetic units per cubic centimeter, and it contains nanomagnetic particleswith an average particle size of less than about 100 nanometers; the average coherence length between adjacent nanomagnetic particles is less than 100 nanometers.

L23 ANSWER 19 OF 77 USPATFULL on STN
AN 2005:111159 USPATFULL
TI Methods of therapy and diagnosis using targeting of cells that express P2Y10
IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
PI US 2005095237 A1 20050505
AI US 2003-648694 A1 20030825 (10)
RLI Continuation-in-part of Ser. No. US 2002-304234, filed on 26 Nov 2002, PENDING Continuation-in-part of Ser. No. US 2002-128558, filed on 22 Apr 2002, PENDING
PRAI US 2001-339453P 20011211 (60)
DT Utility
FS APPLICATION
LREP Elena Quertermous, NUVELO, Inc., 675 Almanor Avenue, Sunnyvale, CA, 94085, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 3365
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Certain cells are capable of expressing P2Y10 RNA. Targeting using P2Y10 polypeptides, nucleic acids encoding for P2Y10 polypeptides and anti-P2Y10 **antibodies**, peptides and small molecules provides a method of killing or inhibiting that growth of cells that express the P2Y10 protein. Methods of therapy and diagnosis of disorders associated with P2Y10 protein-expressing cells, such as P2Y10, are described.

L23 ANSWER 20 OF 77 USPATFULL on STN
AN 2005:92839 USPATFULL
TI Compositions, splice variants and methods relating to breast specific nucleic acids and proteins
IN Macina, Roberto A., San Jose, CA, UNITED STATES
Turner, Leah R., Sunnyvale, CA, UNITED STATES
Sun, Yongming, Redwood City, CA, UNITED STATES
PI US 2005079515 A1 20050414
AI US 2004-852074 A1 20040524 (10)
PRAI US 2003-473016P 20030522 (60)
DT Utility
FS APPLICATION
LREP Licata & Tyrrell P.C., 66 East Main Street, Marlton, NJ, 08053, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 10715
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic breast cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to **antibodies** to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, **antibodies**, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and

treating breast cancer and non-cancerous disease states in breast, identifying breast tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered breast tissue for treatment and research.

L23 ANSWER 21 OF 77 USPATFULL on STN
AN 2005:92457 USPATFULL
TI Medical device with low magnetic susceptibility
IN Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard J., Rochester, NY, UNITED STATES
Gunderman, Robert D., Honeyoye Falls, NY, UNITED STATES
PI US 2005079132 A1 20050414
AI US 2004-914691 A1 20040809 (10)
RLI Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, GRANTED, Pat. No. US 6846985 Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609
DT Utility
FS APPLICATION
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408, US
CLMN Number of Claims: 127
ECL Exemplary Claim: 1
DRWN 52 Drawing Page(s)
LN.CNT 17912
AB An assembly with a substrate, nanomagnetic material and magetoresistive material. The nanomagnetic material has a saturation magentization of from about 2 to about 3000 electromagnetic units per cubic centimeter; and it contains nanomagnetic particles with an average particle size of less than about 100 nanometers. The average coherence length between adjacent nanomagnetic particles is less than 100 nanometers.

L23 ANSWER 22 OF 77 USPATFULL on STN
AN 2005:87417 USPATFULL
TI Antisense oligonucleotide modulation of STAT3 expression
IN Karras, James G., San Marcos, CA, UNITED STATES
PI US 2005074879 A1 20050407
AI US 2004-773678 A1 20040206 (10)
RLI Continuation-in-part of Ser. No. US 2003-713139, filed on 14 Nov 2003, ABANDONED Continuation-in-part of Ser. No. US 2001-758881, filed on 11 Jan 2001, GRANTED, Pat. No. US 6727064 Continuation-in-part of Ser. No. WO 2000-US9054, filed on 6 Apr 2000, PENDING
DT Utility
FS APPLICATION
LREP FENWICK & WEST LLP, 801 CALIFORNIA STREET, MOUNTAIN VIEW, CA, 94014
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7392
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.

L23 ANSWER 23 OF 77 USPATFULL on STN

AN 2005:81108 USPATFULL
TI Targeted ligands
IN Herman, William, Thornhill, CANADA
PI US 2005069549 A1 20050331
AI US 2004-501453 A1 20041122 (10)
WO 2003-CA44 20030114
PRAI CA 2002-2368708 20020114
WO 2002-CA317 20020311
CA 2002-2397169 20020813
CA 2002-2402930 20020919
DT Utility
FS APPLICATION
LREP BERESKIN AND PARR, SCOTIA PLAZA, 40 KING STREET WEST-SUITE 4000 BOX 401, TORONTO, ON, M5H 3Y2
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9273
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention contemplates a composition containing a multispecific ligand containing at least a first ligand binding moiety and a second ligand binding moiety. The first ligand binding moiety specifically binds with a pre-selected first affinity to at least a first ligand. The first ligand has a first biodistribution. The second ligand binding moiety specifically binds with a pre-selected affinity to at least a second ligand. The second ligand has a second biodistribution. The affinity of first and second ligand binding moieties are selected to bias the biodistribution of the multispecific ligand in favour of a selected location of one or both of the ligands.

L23 ANSWER 24 OF 77 USPATFULL on STN
AN 2005:74650 USPATFULL
TI Method of inducing maturation of dendritic cells and uses therefor
IN Li, Jian, Secane, PA, UNITED STATES
Mbow, Lamine, Malvern, PA, UNITED STATES
Goletz, Theresa J., King of Prussia, PA, UNITED STATES
Peritt, David, Cynwyd, PA, UNITED STATES
PI US 2005063944 A1 20050324
AI US 2003-666490 A1 20030919 (10)
DT Utility
FS APPLICATION
LREP PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the induction of responses relating to the maturation of dendritic cells, using IL-18 and IL-18 muteins, and compounds, compositions, methods of making and using thereof, including therapeutic methods and products.

L23 ANSWER 25 OF 77 USPATFULL on STN
AN 2005:56619 USPATFULL
TI Compositions, splice variants and methods relating to colon specific genes and proteins
IN Macina, Roberto A., San Jose, CA, UNITED STATES
Liu, Shu-Hui, Redwood City, CA, UNITED STATES
Vartanian, Steffan F., San Mateo, CA, UNITED STATES
Turner, Leah R., Sunnyvale, CA, UNITED STATES
Tam, Albert, San Francisco, CA, UNITED STATES
PI US 2005048534 A1 20050303
AI US 2004-842738 A1 20040510 (10)
PRAI US 2003-480461P 20030620 (60)
US 2003-469529P 20030509 (60)
DT Utility
FS APPLICATION
LREP Licata & Tyrrell P.C., 66 East Main Street, Marlton, NJ, 08053

CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 38 Drawing Page(s)
LN.CNT 9600
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic colon cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to **antibodies** to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, **antibodies**, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating colon cancer and non-cancerous disease states in colon, identifying colon tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered colon tissue for treatment and research.

L23 ANSWER 26 OF 77 USPATFULL on STN
AN 2005:30800 USPATFULL
TI Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease
IN Georges, Elias, Laval, CANADA
Serfass, Lucile, Montreal, CANADA
Bonneau, Anne-Marie, Laval, CANADA
Dallaire, Frederic, Montreal, CANADA
PA Aurelium BioPharma, Inc. (non-U.S. corporation)
PI US 2005026231 A1 20050203
AI US 2004-801988 A1 20040315 (10)
PRAI US 2003-455005P 20030314 (60)
DT Utility
FS APPLICATION
LREP WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 77
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 5160
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cellular expression of a triosephosphate isomerase (TPI) protein in a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the triosephosphate isomerase protein in a normal cell.

L23 ANSWER 27 OF 77 USPATFULL on STN
AN 2005:30367 USPATFULL
TI Medical device with low magnetic susceptibility
IN Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard Jay, Rochester, NY, UNITED STATES
PI US 2005025797 A1 20050203
AI US 2004-887521 A1 20040707 (10)
RLI Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609
DT Utility
FS APPLICATION

LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408
CLMN Number of Claims: 137
ECL Exemplary Claim: 1
DRWN 42 Drawing Page(s)
LN.CNT 17461
AB An assembly that contains a medical device and biological material within which the medical device is disposed. The assembly has a magnetic susceptibility within the range of plus or minus 1+10.sup.-3 centimeter-gram-seconds

L23 ANSWER 28 OF 77 USPATFULL on STN
AN 2005:17308 USPATFULL
TI Compositions and methods relating to prostate specific genes and proteins
IN Sun, Yongming, Redwood City, CA, UNITED STATES
Liu, Chenghua, San Jose, CA, UNITED STATES
Chen, Sei-Yu, Foster City, CA, UNITED STATES
PI US 2005014710 A1 20050120
AI US 2004-487556 A1 20040824 (10)
WO 2002-US27778 20020829
PRAI US 2001-316257P 20010831 (60)
DT Utility
FS APPLICATION
LREP LICATA & TYRRELL P.C., 66 E. MAIN STREET, MARLTON, NJ, 08053
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8811
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic prostate cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to **antibodies** to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, **antibodies**, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating prostate cancer and non-cancerous disease states in prostate, identifying prostate tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered prostate tissue for treatment and research.

L23 ANSWER 29 OF 77 USPATFULL on STN
AN 2005:16747 USPATFULL
TI Compositions and methods relating to ovary specific genes and proteins
IN Sun, Yongming, Redwood, CA, UNITED STATES
Liu, Chenghua, San Jose, CA, UNITED STATES
Salceda, Susana, San Jose, CA, UNITED STATES
PI US 2005014148 A1 20050120
AI US 2004-487561 A1 20040825 (10)
WO 2002-US27727 20020829
PRAI US 2001-316307P 20010831 (60)
DT Utility
FS APPLICATION
LREP LICATA & TYRRELL P.C., 66 E. MAIN STREET, MARLTON, NJ, 08053
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8370
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to **antibodies** to the polypeptides of the invention, as well as agonists and

antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, **antibodies**, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and non-cancerous disease states in ovarian, identifying ovarian tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered ovarian tissue for treatment and research.

L23 ANSWER 30 OF 77 USPATFULL on STN
AN 2005:10985 USPATFULL
TI Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
IN Georges, Elias, Laval, CANADA
Serfass, Lucile, Montreal, CANADA
Bonneau, Anne-Marie, Laval, CANADA
Dallaire, Frederic, Montreal, CANADA
PA Aurelium BioPharma, Inc. (non-U.S. corporation)
PI US 2005009119 A1 20050113
AI US 2003-737712 A1 20031215 (10)
PRAI US 2002-433351P 20021213 (60)
DT Utility
FS APPLICATION
LREP WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 108
ECL Exemplary Claim: 1
DRWN 23 Drawing Page(s)
LN.CNT 5859
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a nucleophosmin (NPM) protein on the surface of such a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the nucleophosmin protein on the surface of a normal cell.

L23 ANSWER 31 OF 77 USPATFULL on STN
AN 2005:10506 USPATFULL
TI CNGH0005 polypeptides, **antibodies**, compositions, methods and uses
IN Lu, Jin, Boothwyn, PA, UNITED STATES
Yan, Li, Wayne, PA, UNITED STATES
Huang, Chris, Paoli, PA, UNITED STATES
Nakada, Marian, Malvern, PA, UNITED STATES
PI US 2005008638 A1 20050113
AI US 2003-603313 A1 20030625 (10)
PRAI US 2002-391806P 20020627 (60)
DT Utility
FS APPLICATION
LREP PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4830
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to at least one novel CNGH0005 polypeptides, **antibodies**, including isolated nucleic acids that encode at least one CNGH0005 polypeptide or **antibody**, CNGH0005 vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

L23 ANSWER 32 OF 77 USPATFULL on STN
AN 2004:327292 USPATFULL
TI Vimentin directed diagnostics and therapeutics for multidrug resistant

neoplastic disease
IN Georges, Elias, Laval, CANADA
Serfass, Lucile, Montreal, CANADA
Bonneau, Anne-Marie, Laval, CANADA
Dallaire, Frederic, Montreal, CANADA
PA Aurelium BioPharma Inc. (non-U.S. corporation)
PI US 2004259112 A1 20041223
AI US 2003-736889 A1 20031215 (10)
PRAI US 2002-433480P 20021213 (60)
DT Utility
FS APPLICATION
LREP WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 108
ECL Exemplary Claim: 1
DRWN 21 Drawing Page(s)
LN.CNT 5789
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods for detecting multidrug resistance in neoplastic or damaged cells or multidrug resistant (MDR) neoplastic or damaged cells by detecting an increase in the cell surface expression of vimentin protein in such cells as compared to the level of cell surface expression of vimentin protein in a normal cell or a non-MDR neoplastic cell.

L23 ANSWER 33 OF 77 USPATFULL on STN
AN 2004:323230 USPATFULL
TI Tissue collection devices containing biosensors
IN Kayyem, Jon Faiz, Pasadena, CA, United States
PA Clinical Micro Sensors, Inc., Pasadena, CA, United States (U.S. corporation)
PI US 6833267 B1 20041221
AI US 1999-472657 19991227 (9)
PRAI US 1998-114178P 19981230 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Whisenant, Ethan; Assistant Examiner: Lu, Wei
LREP Dorsey & Whitney LLP, Silva, Robin M., Kosslak, Renee M.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 4453
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present disclosure provides tissue collection devices comprising biosensors that can be used for the detection of target analytes, such as nucleic acids and proteins, including **antibodies** and enzymes.

L23 ANSWER 34 OF 77 USPATFULL on STN
AN 2004:321764 USPATFULL
TI Therapeutic assembly
IN Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard J., Rochester, NY, UNITED STATES
Lanzafame, John, Victor, NY, UNITED STATES
Weiner, Michael L., Webster, NY, UNITED STATES
Connelly, Patrick R., Rochester, NY, UNITED STATES
PI US 2004254419 A1 20041216
AI US 2004-867517 A1 20040614 (10)
RLI Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING
DT Utility

FS APPLICATION
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408
CLMN Number of Claims: 175
ECL Exemplary Claim: CLM-1-177
DRWN 40 Drawing Page(s)
LN.CNT 16208
AB A therapeutic assembly that contains a therapeutic agent, a ctyotoxic radioactive material, and a nanomagnetic material with nanomagnetic particles. The nanomagentic particles have an average particle size of less than about 100 nanometers; and the average coherence length between adjacent nanomagnetic particles is less than 100 nanometers. The nanomagnetic material has a saturation magentization of from about 2 to about 3000 electromagnetic units per cubic centimeter, a phase transition temperature of from about 40 to about 200 degrees Celsius, and a saturation magnetization of from about 2 to about 3,000 electromagnetic units per cubic centimeter

L23 ANSWER 35 OF 77 USPATFULL on STN
AN 2004:286782 USPATFULL
TI Methods and compositions of novel triazine compounds
IN Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES
Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Yeleswarapu, Koteswar Rao, Hyderabad, INDIA
Pal, Manojit, Hyderabad, INDIA
Reddy, Jangalgar Tirupathy, Hyderabad, INDIA
Reddy, Velagala Venkira Rama Murali Krishna, Hyderabad, INDIA
Sridevi, Bhatlapenumarphy Shesha, Hyderabad, INDIA
Kumar, Potlapally Rajender, Hyderabad, INDIA
Reddy, Gaddam Om, Hyderabad, INDIA
PI US 2004224950 A1 20041111
AI US 2003-400140 A1 20030326 (10)
RLI Continuation-in-part of Ser. No. US 2003-390485, filed on 17 Mar 2003, PENDING Continuation of Ser. No. US 2002-253388, filed on 23 Sep 2002, ABANDONED
PRAI US 2001-324147P 20010921 (60)
DT Utility
FS APPLICATION
LREP JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100 PEACHTREE STREET, ATLANTA, GA, 30309
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 86 Drawing Page(s)
LN.CNT 11181
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

L23 ANSWER 36 OF 77 USPATFULL on STN
AN 2004:268339 USPATFULL
TI Methods and compositions of novel triazine compounds
IN Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES
Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Yeleswarapu, Koteswar Rao, Hyderabad, INDIA
Pal, Manojit, Hyderabad, INDIA
Reddy, Jangalgar Tirupathy, Hyderabad, INDIA

Krishma Reddy, Velagala Venkata Rama Murali, Hyderabad, INDIA
Sesila Sridevi, Bhatlapenumarthy, Hyderabad, INDIA
Kumar, Potlapally Rajender, Hyderabad, INDIA
Reddy, Gaddam Om, Hyderabad, INDIA
PI US 2004209882 A1 20041021
AI US 2003-400169 A1 20030326 (10)
DT Utility
FS APPLICATION
LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA, 30357-0037
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 86 Drawing Page(s)
LN.CNT 12036
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

L23 ANSWER 37 OF 77 USPATFULL on STN
AN 2004:268338 USPATFULL
TI Methods and compositions of novel triazine compounds
IN Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES
Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Yeleswarapu, Koteswar Rao, Hydrabad, INDIA
Pal, Manojit, Hydrabad, INDIA
Reddy, Jangalgar Tirupathy, Hydrabad, INDIA
Krishna Reddy, Velagala Venkata Rama Murali, Hydrabad, INDIA
Sridevi, Bhatlapenumarthy Sesha, Hydrabad, INDIA
Kumar, Potlapally Rajender, Hyderbad, INDIA
Reddy, Gaddam Om, Hydrabad, INDIA
PI US 2004209881 A1 20041021
AI US 2003-400134 A1 20030326 (10)
DT Utility
FS APPLICATION
LREP JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100 PEACHTREE STREET, ATLANTA, GA, 30309
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 86 Drawing Page(s)
LN.CNT 9019
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

L23 ANSWER 38 OF 77 USPATFULL on STN
AN 2004:268337 USPATFULL
TI Methods and compositions of novel triazine compounds
IN Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES

Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Yeleswarapu, Koteswar Rao, Begumpet, INDIA
Pal, Manojit, Miyapur, INDIA
Reddy, Jangalgar Tirupathy, Miyapur, INDIA
Krlshna Reddy, Velagala Venkata Rama Murali, Kukatpally, INDIA
Sridevi, Bhatlapenumarthy Sesha, Gandhinagar, INDIA
Kumar, Potlapally Rajender, Miyapur, INDIA
Reddy, Gaddam Om, Miyapur, INDIA
PI US 2004209880 A1 20041021
AI US 2003-397968 A1 20030326 (10)
DT Utility
FS APPLICATION
LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA, 30357-0037
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 86 Drawing Page(s)
LN.CNT 10190
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

L23 ANSWER 39 OF 77 USPATFULL on STN
AN 2004:239705 USPATFULL
TI HSC70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
IN Georges, Elias, Laval, CANADA
Serfass, Lucile, Montreal, CANADA
Bonneau, Anne-Marie, Laval, CANADA
Dallaire, Frederic, Montreal, CANADA
PA Aurelium BioPharma, Inc. (non-U.S. corporation)
PI US 2004185511 A1 20040923
AI US 2003-737350 A1 20031215 (10)
PRAI US 2003-438012P 20030103 (60)
DT Utility
FS APPLICATION
LREP WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109
CLMN Number of Claims: 108
ECL Exemplary Claim: 1
DRWN 30 Drawing Page(s)
LN.CNT 5612
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cell surface expression of a heat shock cognate (HSC70) protein 70 on the surface of such a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the HSC70 protein on the surface of a normal cell.

L23 ANSWER 40 OF 77 USPATFULL on STN
AN 2004:239644 USPATFULL
TI MCP-1 mutant proteins, **antibodies**, compositions, methods and uses
IN Heavner, George A., Malvern, PA, UNITED STATES
Das, Anuk, Malvern, PA, UNITED STATES
PI US 2004185450 A1 20040923
AI US 2003-393804 A1 20030321 (10)
DT Utility

FS APPLICATION
LREP PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3710
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to at least one novel MCP-1 mutant proteins, **antibodies**, including isolated nucleic acids that encode at least one MCP-1 mutant protein or **antibody**, MCP-1 mutant vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including herapeutic compositions, methods and devices.

L23 ANSWER 41 OF 77 USPATFULL on STN
AN 2004:221352 USPATFULL
TI Methods for preparing Bacillus **anthracis** sporulation deficient mutants and for producing recombinant Bacillus **anthracis** protective antigen for use in vaccines
IN Leppla, Stephen H., Bethesda, MD, UNITED STATES
Rosovitz, Mary Jo, Kensington, MD, UNITED STATES
Hsu, S. Dana, Bethesda, MD, UNITED STATES
PI US 2004171121 A1 20040902
AI US 2003-638006 A1 20030808 (10)
PRAI US 2002-402285P 20020809 (60)
DT Utility
FS APPLICATION
LREP KLARQUIST SPARKMAN, LLP, 121 S.W. SALMON STREET, SUITE #1600, ONE WORLD TRADE CENTER, PORTLAND, OR, 97204-2988
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1786
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to improved methods of producing and recovering sporulation-deficient B. **anthracis** mutant stains, and for producing and recovering recombinant B. **anthracis** protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. **anthracis** bacterial infections and which are useful to prevent and/or treat illnesses caused by B. **anthracis**, such as inhalation **anthrax**, cutaneous **anthrax** and gastrointestinal **anthrax**.

L23 ANSWER 42 OF 77 USPATFULL on STN
AN 2004:203967 USPATFULL
TI Pyrrolidones with anti-HIV activity
IN Wu, Baogen, San Diego, CA, UNITED STATES
He, Yun, San Diego, CA, UNITED STATES
Ngyuen, Truc, San Diego, CA, UNITED STATES
Kuhen, Kelli L., Carlsbad, CA, UNITED STATES
Ellis, David Archer, San Diego, CA, UNITED STATES
Jiang, Tao, San Diego, CA, UNITED STATES
Xe, Xiaohui, San Diego, CA, UNITED STATES
Yang, Kunyong, San Diego, CA, UNITED STATES
Bursulaya, Badry, San Diego, CA, UNITED STATES
PA IRM LLC, a Delaware LLC, Hamilton HM LX, BERMUDA (U.S. corporation)
PI US 2004157859 A1 20040812
AI US 2003-690873 A1 20031021 (10)
PRAI US 2002-422619P 20021030 (60)
US 2002-420480P 20021021 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 22

ECL Exemplary Claim: 1
DRWN 101 Drawing Page(s)
LN.CNT 3331
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to inhibition of viruses, e.g., HIV using pyrrolidones and compounds related to pyrrolidones. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS.

L23 ANSWER 43 OF 77 USPATFULL on STN
AN 2004:197449 USPATFULL
TI Oxindoles with anti-HIV activity
IN He, Yun, San Diego, CA, UNITED STATES
Jiang, Tao, San Diego, CA, UNITED STATES
Kuhen, Kelli L., Carlsbad, CA, UNITED STATES
Ellis, David Archer, San Diego, CA, UNITED STATES
Wu, Baogen, San Diego, CA, UNITED STATES
Wu, Tom Yao-Hsiang, La Jolla, CA, UNITED STATES
Bursulaya, Badry, San Diego, CA, UNITED STATES
PA IRM LLC, a Delaware LLC, Hamilton, BERMUDA (U.S. corporation)
PI US 2004152755 A1 20040805
AI US 2003-690802 A1 20031021 (10)
PRAI US 2002-420482P 20021021 (60)
US 2002-420481P 20021021 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 21 Drawing Page(s)
LN.CNT 2180
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to inhibition of viruses, e.g., HIV using oxindoles and compounds related to oxindoles. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS.

L23 ANSWER 44 OF 77 USPATFULL on STN
AN 2004:197413 USPATFULL
TI Quinolones with anti-HIV activity
IN He, Yun, San Diego, CA, UNITED STATES
Ellis, David Archer, San Diego, CA, UNITED STATES
Anaclerio, Beth Marie, San Diego, CA, UNITED STATES
Kuhen, Kelli L., Carlsbad, CA, UNITED STATES
Wu, Baogen, San Diego, CA, UNITED STATES
Jiang, Tao, San Diego, CA, UNITED STATES
PA IRM LLC, a Delaware LLC, Hamilton, HM LX, BERMUDA (U.S. corporation)
PI US 2004152719 A1 20040805
AI US 2003-690738 A1 20031021 (10)
PRAI US 2002-420163P 20021021 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 2027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to inhibition of viruses, e.g., HIV using quinolones and compounds related to quinolones. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to HIV infection and related

disease states such as AIDS.

L23 ANSWER 45 OF 77 USPATFULL on STN
AN 2004:190129 USPATFULL
TI Tissue collection devices containing biosensors
IN Kayyem, Jon Faiz, Pasadena, CA, UNITED STATES
PI US 2004146899 A1 20040729
AI US 2003-697908 A1 20031029 (10)
RLI Division of Ser. No. US 1999-472657, filed on 27 Dec 1999, PENDING
PRAI US 1998-114178P 19981230 (60)
DT Utility
FS APPLICATION
LREP Robin M. Silva, DORSEY & WHITNEY LLP, Suite 3400, Four Embarcadero Center, San Francisco, CA, 94111-4187
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 4085
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to tissue collection devices such as blood collection devices that comprise biosensors for the detection of target analytes such as nucleic acids and proteins, including **antibodies** and enzymes.

L23 ANSWER 46 OF 77 USPATFULL on STN
AN 2004:158159 USPATFULL
TI CNGH0004 polypeptides, **antibodies**, compositions, methods and uses
IN Song, Xiao-Yu R., West Chester, PA, UNITED STATES
Huang, Chris, Paoli, PA, UNITED STATES
PI US 2004120956 A1 20040624
AI US 2003-603283 A1 20030625 (10)
PRAI US 2002-391834P 20020627 (60)
DT Utility
FS APPLICATION
LREP PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5563
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to at least one novel CNGH0004 polypeptides, **antibodies**, including isolated nucleic acids that encode at least one CNGH0004 polypeptide or **antibody**, CNGH0004 vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

L23 ANSWER 47 OF 77 USPATFULL on STN
AN 2004:144199 USPATFULL
TI Methods of therapy and diagnosis using targeting of cells that express Ly-9
IN Emtage, Peter, Sunnyvale, CA, UNITED STATES
PI US 2004109863 A1 20040610
AI US 2002-328538 A1 20021223 (10)
RLI Continuation-in-part of Ser. No. US 2002-310612, filed on 4 Dec 2002, PENDING
DT Utility
FS APPLICATION
LREP Luisa Bigornia, HYSEQ, INC., 670 Almanor Avenue, Sunnyvale, CA, 94085
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 2586
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Certain cells, including types of cancer cells such as Ly-9, are capable of expressing Ly-9 RNA. Immunotargeting using Ly-9 polypeptides, nucleic acids encoding for Ly-9 polypeptides and anti-Ly-9 **antibodies**

provides a method of killing or inhibiting that growth of cancer cells that express the Ly-9 protein. Methods of immunotherapy and diagnosis of disorders associated with Ly-9 protein-expressing cells, such as Ly-9, are described.

L23 ANSWER 48 OF 77 USPATFULL on STN
AN 2004:144198 USPATFULL
TI Methods of therapy and diagnosis using targeting of cells that express Ly-9
IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
PI US 2004109862 A1 20040610
AI US 2002-310612 A1 20021204 (10)
DT Utility
FS APPLICATION
LREP Luisa Bigornia, HYSEQ, INC., 670 Almanor Avenue, Sunnyvale, CA, 94085
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 2517
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Certain cells, including types of cancer cells such as Ly-9, are capable of expressing Ly-9 RNA. Immunotargeting using Ly-9 polypeptides, nucleic acids encoding for Ly-9 polypeptides and anti-Ly-9 **antibodies** provides a method of killing or inhibiting that growth of cancer cells that express the Ly-9 protein. Methods of immunotherapy and diagnosis of disorders associated with Ly-9 protein-expressing cells, such as Ly-9, are described.

L23 ANSWER 49 OF 77 USPATFULL on STN
AN 2004:107606 USPATFULL
TI Process for detecting increased risk of fetal chromosomal abnormality
IN Yamamoto, Ritsu, Sapporo-shi, JAPAN
Satomura, Shinji, Osaka-shi, JAPAN
PA WAKO PURE CHEMICAL INDUSTRIES, LTD., Osaka, JAPAN (non-U.S. corporation)
PI US 2004082006 A1 20040429
AI US 2003-686682 A1 20031017 (10)
RLI Division of Ser. No. US 1999-241085, filed on 1 Feb 1999, GRANTED, Pat. No. US 6677123
PRAI JP 1998-38186 19980203
DT Utility
FS APPLICATION
LREP ARMSTRONG, KRATZ, QUINTOS, HANSON & BROOKS, LLP, 1725 K STREET, NW, SUITE 1000, WASHINGTON, DC, 20006
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 857
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An increased risk of a fetal chromosomal abnormality, for example, fetal Down syndrome can be detected by separating or discriminating α-fetoproteins present in the body fluid of a pregnant woman, and measuring the proportion of one or more of the α-fetoproteins which have a specific sugar chain structure, relative to the total α-fetoproteins.

L23 ANSWER 50 OF 77 USPATFULL on STN
AN 2004:101778 USPATFULL
TI Methods and compositions of novel triazine compounds
IN Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES
Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Campbell, Karen A., Durham, NC, UNITED STATES
PI US 2004077648 A1 20040422
AI US 2003-390485 A1 20030317 (10)
RLI Continuation of Ser. No. US 2002-253388, filed on 23 Sep 2002, ABANDONED
PRAI US 2001-324147P 20010921 (60)
DT Utility
FS APPLICATION

LREP JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100 PEACHTREE STREET, SUITE 2800, ATLANTA, GA, 30309
CLMN Number of Claims: 75
ECL Exemplary Claim: 1
DRWN 54 Drawing Page(s)
LN.CNT 10058
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

L23 ANSWER 51 OF 77 USPATFULL on STN
AN 2004:100777 USPATFULL
TI Methods for preparing bacillus **anthracis** protective antigen for use in vaccines
IN Shiloach, Joseph, Rockville, MD, UNITED STATES
Leppla, Stephen H., Bethesda, MD, UNITED STATES
Ramirez, Delia M., Bethesda, MD, UNITED STATES
Schneerson, Rachel, Bethesda, MD, UNITED STATES
Robbins, John B., Chevy Chase, MD, UNITED STATES
PI US 2004076638 A1 20040422
AI US 2002-290712 A1 20021108 (10)
PRAI US 2001-344505P 20011109 (60)
DT Utility
FS APPLICATION
LREP KLARQUIST SPARKMAN, LLP, 121 S.W. SALMON STREET, SUITE #1600, ONE WORLD TRADE CENTER, PORTLAND, OR, 97204-2988
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1273
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to improved methods of producing and recovering B. **anthracisprotective** antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. **anthracis** bacterial infections and which are useful to prevent and/or treat illnesses caused by B. **anthracis**, such as inhalation **anthrax**, cutaneous **anthrax** and gastrointestinal **anthrax**.

L23 ANSWER 52 OF 77 USPATFULL on STN
AN 2004:64298 USPATFULL
TI Methods of immunotherapy and diagnosis
IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Wang, Zhiwei, Sunnyvale, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
PI US 2004048817 A1 20040311
AI US 2002-304234 A1 20021126 (10)
RLI Continuation-in-part of Ser. No. US 2002-128558, filed on 22 Apr 2002, PENDING
PRAI US 2001-339453P 20011211 (60)
DT Utility
FS APPLICATION
LREP Elena Quertermous, NUVELO, 670 Almanor Avenue, Sunnyvale, CA, 94085
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2808

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Certain cells, including types of cancer cells such as T-cell lymphoma, T-cell leukemia, multiple myeloma, and chronic myeloid leukemia, B cell lymphoma of mature B cell lineage, non-Hodgkin's lymphoma of mature B-cell lineage, and Burkitt's lymphoma of mature B cell lineage, are capable of expressing SEQ ID NO: 2 or 4-ecoding RNA. Immunotargeting using SEQ ID NO: 2 or 4 polypeptides, nucleic acids encoding for SEQ ID NO: 2 or 4 polypeptides and anti-SEQ ID NO: 2 or 4 **antibodies** provides a method of killing or inhibiting that growth of cancer cells that express the SEQ ID NO: 2 or 4 protein. Methods of immunotherapy and diagnosis of disorders associated with SEQ ID NO: 2 or 4 protein-expressing cells, such as T-cell lymphoma, T-cell leukemia, multiple myeloma, and chronic myeloid leukemia, B cell lymphoma of mature B cell lineage, non-Hodgkin's lymphoma of mature B-cell lineage, and Burkitt's lymphoma of mature B cell lineage, are described.

L23 ANSWER 53 OF 77 USPATFULL on STN
AN 2004:51781 USPATFULL
TI Sphingolipid derivatives and their methods of use
IN Liotta, Dennis C., McDonough, GA, UNITED STATES
Merrill, Alfred H., JR., Dunwoody, GA, UNITED STATES
Keane, Thomas E., Dunwoody, GA, UNITED STATES
Bhalla, Kapil N., Atlanta, GA, UNITED STATES
Schmelz, Eva M., Atlanta, GA, UNITED STATES
PI US 2004039212 A1 20040226
AI US 2003-647801 A1 20030825 (10)
RLI Continuation of Ser. No. US 1999-249211, filed on 12 Feb 1999, GRANTED, Pat. No. US 6610835
PRAI US 1998-74536P 19980212 (60)
DT Utility
FS APPLICATION
LREP KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 4250
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Derivatives of sphingolipids of the formula: ##STR1##

are provided wherein the substituents are as defined in the specification and wherein there is at least one R.sup.2 substituent in the sphingolipid derivative. The compounds are useful in the treatment of of abnormal cell proliferation, including benign and malignant tumors, the promotion of cell differentiation, the induction of apoptosis, the inhibition of protein kinase C, and the treatment of inflammatory conditions, psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue. The invention also includes a method for triggering the release of cytochrome c from mitochondria that includes administering an effective amount of a sphingolipid or its derivative or prodrug to a host in need thereof. Further, the invention provides a method for treating bacterial infections, including those that influence colon cancer and other disorders of the intestine, that includes administering an effective amount of one of the active compounds identified herein.

L23 ANSWER 54 OF 77 USPATFULL on STN
AN 2004:44554 USPATFULL
TI Novel microarrays and methods of use thereof
IN Wang, Denong, Middletown City, NY, UNITED STATES
PA The Trustees of Columbia University in the City of New York (U.S. corporation)
PI US 2004033546 A1 20040219
AI US 2003-367204 A1 20030214 (10)
RLI Continuation-in-part of Ser. No. US 2002-280376, filed on 24 Oct 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US11612, filed on 10 Apr 2002, PENDING
DT Utility
FS APPLICATION

LREP John P. White, Esq., COOPER & DUNHAM LLP, 1185 Avenue of the Americas, New York, NY, 10036
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 31 Drawing Page(s)
LN.CNT 4905
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides novel nitrocellulose-based or Hydrogel-based microarrays and methods of making and using them (1) to detect the presence of one or more agents in a sample, (2) to determine the amount of one or more agents in a sample, (3) to determine whether a subject is afflicted with a disorder, and (4) to determine whether an agent known to specifically bind to a first compound also specifically binds to a second compound. This invention also provides kits which comprise the instant microarrays. This invention further provides **antibodies** capable of specifically binding to a glycomer present both on the surface of a mammalian macrophage or intestinal epithelial cell, and on a bacterial cell. Finally, this invention provides diagnostic methods using the instant **antibodies**.

L23 ANSWER 55 OF 77 USPATFULL on STN
AN 2004:31728 USPATFULL
TI Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
IN Dedera, Douglas, Castro Valley, CA, UNITED STATES
Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
PI US 2004023870 A1 20040205
AI US 2002-327491 A1 20021219 (10)
RLI Continuation-in-part of Ser. No. US 2002-302444, filed on 22 Nov 2002, PENDING Continuation-in-part of Ser. No. US 2002-77676, filed on 14 Feb 2002, PENDING Continuation-in-part of Ser. No. US 2000-687527, filed on 12 Oct 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-488725, filed on 21 Jan 2000, PENDING
DT Utility
FS APPLICATION
LREP Renee S. Polizotto, 675 Almanor Avenue, Sunnyvale, CA, 94085
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 3553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Certain cells, including types of cancer cells such as B-cell lymphomas, T cell lymphomas, Hodgkin's disease and myeloid leukemias, are capable of expressing Toll-like Receptor 9 (TLR9) or Toll-like Receptor 10 (TLR10) mRNA. Immunotargeting using TLR9 or TLR10 polypeptides, nucleic acids encoding for TLR9 or TLR10 polypeptides and anti-TLR9 or anti-TLR10 **antibodies** provides a method of killing or inhibiting that growth of cancer cells that express the TLR9 or TLR10 protein. Methods of immunotherapy and diagnosis of disorders associated with TLR9 or TLR10 protein-expressing cells, such as B-cell lymphoma, T cell lymphoma, acute myeloid leukemia, Hodgkin's disease, B cell leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia and myelodysplastic syndromes, are described.

L23 ANSWER 56 OF 77 USPATFULL on STN
AN 2004:31197 USPATFULL
TI Mut-IL-18 or Mut-IL-18R proteins, **antibodies**, compositions, methods and uses
IN Heavner, George A., Malvern, PA, UNITED STATES
Snyder, Linda A., Pottstown, PA, UNITED STATES
McCarthy, Stephen G., West Chester, PA, UNITED STATES
PI US 2004023336 A1 20040205
AI US 2002-280609 A1 20021025 (10)
PRAI US 2001-335880P 20011026 (60)
DT Utility
FS APPLICATION
LREP PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 57

ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 4447
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to at least one novel Mut-IL18 or Mut-IL-18R proteins, **antibodies**, including isolated nucleic acids that encode at least one Mut-IL18 or Mut-IL-18R protein or **antibody**, Mut-IL18 or Mut-IL-18R vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

L23 ANSWER 57 OF 77 USPATFULL on STN
AN 2004:30649 USPATFULL
TI Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
IN Dedea, Douglas, Castro Valley, CA, UNITED STATES
PI US 2004022786 A1 20040205
AI US 2002-302444 A1 20021122 (10)
RLI Continuation-in-part of Ser. No. US 2002-77676, filed on 14 Feb 2002, PENDING Continuation-in-part of Ser. No. US 2000-687527, filed on 12 Oct 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-488725, filed on 21 Jan 2000, PENDING
DT Utility
FS APPLICATION
LREP Luisa Bigornia, HYSEQ, INC., 670 Almanor Avenue, Sunnyvale, CA, 94085
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 3161
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Certain cells, including types of cancer cells such as B-cell lymphomas, T cell lymphomas, Hodgkin's disease and myeloid leukemias, are capable of expressing Toll-like Receptor 9 (TLR9) or Toll-like Receptor 10 (TLR10) mRNA. Immunotargeting using TLR9 or TLR10 polypeptides, nucleic acids encoding for TLR9 or TLR10 polypeptides and anti-TLR9 or anti-TLR10 **antibodies** provides a method of killing or inhibiting that growth of cancer cells that express the TLR9 or TLR10 protein. Methods of immunotherapy and diagnosis of disorders associated with TLR9 or TLR10 protein-expressing cells, such as B-cell lymphoma, T cell lymphoma, acute myeloid leukemia, Hodgkin's disease, B cell leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia and myelodysplastic syndromes, are described.

L23 ANSWER 58 OF 77 USPATFULL on STN
AN 2004:12651 USPATFULL
TI Administration of agents for the treatment of inflammation
IN Taylor, Julie, San Francisco, CA, UNITED STATES
Yednock, Theodore A., Forest Knolls, CA, UNITED STATES
PI US 2004009169 A1 20040115
AI US 2003-372111 A1 20030225 (10)
PRAI US 2002-374501P 20020423 (60)
US 2002-360134P 20020225 (60)
DT Utility
FS APPLICATION
LREP BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 2733
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.

L23 ANSWER 59 OF 77 USPATFULL on STN
AN 2004:9529 USPATFULL
TI Process for detecting increased risk of fetal chromosomal abnormality
IN Yamamoto, Ritsu, Sapporo, JAPAN
Satomura, Shinji, Osaka, JAPAN
PA Wako Pure Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)
PI US 6677123 B1 20040113
AI US 1999-241085 19990201 (9)
PRAI JP 1998-38186 19980203
DT Utility
FS GRANTED
EXNAM Primary Examiner: Le, Long V.; Assistant Examiner: Cook, Lisa V.
LREP Armstrong, Kratz , Quintos, Hanson & Brooks, LLP
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 954
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An increased risk of a fetal chromosomal abnormality, for example, fetal Down syndrome can be detected by separating or discriminating α-fetoproteins present in the body fluid of a pregnant woman, and measuring the proportion of one or more of the α-fetoproteins which have a specific sugar chain structure, relative to the total α-fetoproteins.

L23 ANSWER 60 OF 77 USPATFULL on STN
AN 2004:7358 USPATFULL
TI Materials and methods relating to therapy and diagnosis using targeting of cells that express DCAL-Hy polypeptides
IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
Goodrich, Ryle W., Los Angeles, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
PI US 2004005592 A1 20040108
AI US 2003-379127 A1 20030303 (10)
RLI Continuation-in-part of Ser. No. US 2001-799451, filed on 5 Mar 2001, PENDING
DT Utility
FS APPLICATION
LREP NUVELO, 675 ALMANOR AVE., SUNNYVALE, CA, 94085
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 7657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to novel human DCAL-Hy polypeptides. Other aspects of the invention include vectors containing processes for producing novel human DCAL-Hy polypeptides, and **antibodies** specific for such polypeptides. Targeting DCAL-Hy using DCAL-Hy polypeptides, nucleic acids encoding for DCAL-Hy polypeptides, anti-DCAL-Hy **antibodies**, and other binding peptides and small molecules provides a method of killing or inhibiting that growth of cancer cells that express the DCAL-Hy protein. Methods of therapy and diagnosis of disorders associated with DCAL-Hy protein-expressing cells, such as DCAL-Hy, are described.

L23 ANSWER 61 OF 77 USPATFULL on STN
AN 2004:7084 USPATFULL
TI Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
IN Dedera, Douglas, Castro Valley, CA, UNITED STATES
Wang, Jian-Rui, Cupertino, CA, UNITED STATES
Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
PI US 2004005317 A1 20040108
AI US 2002-327413 A1 20021219 (10)
RLI Continuation-in-part of Ser. No. US 2002-78080, filed on 15 Feb 2002, PENDING Continuation-in-part of Ser. No. WO 2001-US2613, filed on 25 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-645476, filed on

24 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-491404, filed on 25 Jan 2000, ABANDONED
DT Utility
FS APPLICATION
LREP Luisa Bigornia, HYSEQ, INC., 670 Almanor Avenue, Sunnyvale, CA, 94085
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2703
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 **antibodies** provides a method of killing or inhibiting that growth of CD84HY1Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of disorders associated with CD84Hy1protein-expressing cells are described.

L23 ANSWER 62 OF 77 USPATFULL on STN
AN 2003:306021 USPATFULL
TI Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein
IN Dedera, Douglas A., Castro Valley, CA, UNITED STATES
Chen, Huang-Tsu, Cupertino, CA, UNITED STATES
Wan, Ching-Yi, Alviso, CA, UNITED STATES
PI US 2003215453 A1 20031120
AI US 2002-146619 A1 20020514 (10)
DT Utility
FS APPLICATION
LREP Luisa Bigornia, HYSEQ, INC., 670 Almanor Avenue, Sunnyvale, CA, 94085
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2466
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Certain cells, including types of cancer cells such as B-cell lymphoma, T-cell lymphoma, T-cell leukemia, and non-Hodgkin's lymphoma, are capable of expressing VpreB1 RNA. Immunotargeting using VpreB1 polypeptides, nucleic acids encoding for VpreB1 polypeptides and anti-VpreB1 **antibodies** provides a method of killing or inhibiting that growth of cancer cells that express the VpreB1 protein. Methods of immunotherapy and diagnosis of disorders associated with VpreB1 protein-expressing cells, such as B-cell lymphoma, T-cell lymphoma, T-cell leukemia, and non-Hodgkin's lymphoma, are described.

L23 ANSWER 63 OF 77 USPATFULL on STN
AN 2003:282611 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003198954 A1 20031023
AI US 2001-1142 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25681
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such

GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L23 ANSWER 64 OF 77 USPATFULL on STN
AN 2003:264856 USPATFULL
TI Interfacial biomaterials
IN Grinstaff, Mark W., Durham, NC, UNITED STATES
Kenan, Daniel J., Chapel Hill, NC, UNITED STATES
Walsh, Elisabeth B., Durham, NC, UNITED STATES
Middleton, Crystan, Arlington, VA, UNITED STATES
PI US 2003185870 A1 20031002
AI US 2002-300694 A1 20021120 (10)
PRAI US 2001-331843P 20011120 (60)
DT Utility
FS APPLICATION
LREP JENKINS & WILSON, PA, 3100 TOWER BLVD, SUITE 1400, DURHAM, NC, 27707
CLMN Number of Claims: 229
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4272
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An interfacial biomaterial prepared using a plurality of binding agents, each binding agent including a first ligand that specifically binds a non-biological substrate and a second ligand that specifically binds a biological substrate. Also provided is an interfacial biomaterial prepared using a plurality of binding agents, each binding agent including a ligand that specifically binds a non-biological substrate and a non-binding domain that shows substantially no binding to a biological substrate. Also provided are methods for preparing a binding agent, methods for preparing an interfacial biomaterial, and methods for using interfacial biomaterials.

L23 ANSWER 65 OF 77 USPATFULL on STN
AN 2003:251707 USPATFULL
TI N-substituted Dithiocarbamates for the Treatment of Biological Disorders
IN Medford , Russell M., 7935 Fawndale Way, Atlanta, Georgia, UNITED STATES 30350
Uday , Saxena, 2900 Galahad Drive, Atlanta, Georgia, UNITED STATES 30034
Hoong , Lee K., 220 Gaines Oak Way, Suwanee, Georgia, UNITED STATES 30024
Somers , Patricia K., 201 Yale Way, Fort Collins, Colorado, UNITED STATES 80525
PA AtheroGenics, Inc., Alpharetta, 30004, UNITED STATES, Georgia (U.S. individual)
PI US 2003176496 A1 20030918
US 6747061 B2 20040608
AI US 2001-815244 A1 20010321 (9)
PRAI US 2000-60190790 20000321
DT Utility
FS APPLICATION
LREP Sherry, Knowles, King & Spalding , 191 Peachtree Street, Atlanta, Georgia, 30303
CLMN Number of Claims: 79
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 3269
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Abstract of Disclosure

N-substituted dithiocarbamate esters in which the amine function bears a hydrogen are provides, as are methods for using the compounds in the treatment of cellular hyperproliferation and VCAM-1 mediated disease. Particularly provided is a method of treating a hyperproliferative

disorder such as cancer comprising administering an antiproliferative agent in combination with a potentiating effective amount of a N-substituted dithiocarbamate ester. Also provided are methods of using the compounds in the treatment of VCAM-1 mediated diseases such as inflammation and carrdiovascular disease.

L23 ANSWER 66 OF 77 USPATFULL on STN
AN 2003:244219 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003170628 A1 20030911
AI US 2001-999570 A1 20011114 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25549
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L23 ANSWER 67 OF 77 USPATFULL on STN
AN 2003:231986 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003162186 A1 20030828
AI US 2002-154678 A1 20020522 (10)
PRAI US 2001-293574P 20010525 (60)
US 2001-298698P 20010615 (60)
US 2001-302277P 20010629 (60)
US 2001-305456P 20010713 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L23 ANSWER 68 OF 77 USPATFULL on STN
AN 2003:228401 USPATFULL
TI Sphingolipid derivatives and their methods of use

IN Liotta, Dennis C., McDonough, GA, United States
Merrill, Jr., Alfred H., Stone Mountain, GA, United States
Keane, Thomas E., Dunwoody, GA, United States
Bhalla, Kapil N., Atlanta, GA, United States
Schmelz, Eva M, Atlanta, GA, United States4)
PA Emory University, Atlanta, GA, United States (U.S. corporation)
PI US 6610835 B1 20030826
AI US 1999-249211 19990212 (9)
PRAI US 1998-74536P 19980212 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wilson, James O.; Assistant Examiner: Maier, Leigh C.
LREP King & Spalding LLP, Knowles, Sherry M.
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 18 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 4123
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Derivatives of sphingolipids of the formula: ##STR1##

are provided wherein the substituents are as defined in the specification and wherein there is at least one R.sup.2 substituent in the sphingolipid derivative. The compounds are useful in the treatment of of abnormal cell proliferation, including benign and malignant tumors, the promotion of cell differentiation, the induction of apoptosis, the inhibition of protein kinase C; and the treatment of inflammatory conditions, psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue. The invention also includes a method for triggering the release of cytochrome c from mitochondria that includes administering an effective amount of a sphingolipid or its derivative or prodrug to a host in need thereof. Further, the invention provides a method for treating bacterial infections, including those that influence colon cancer and other disorders of the intestine, that includes administering an effective amount of one of the active compounds identified herein.

L23 ANSWER 69 OF 77 USPATFULL on STN
AN 2003:225673 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003157485 A1 20030821
AI US 2001-992095 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25484
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L23 ANSWER 70 OF 77 USPATFULL on STN

AN 2003:140939 USPATFULL
TI IL-8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma
IN Masood, Rizwan, Walnut, CA, UNITED STATES
Gill, Parkash S., Agoura, CA, UNITED STATES
PA University of Southern California, Los Angeles, CA (U.S. corporation)
PI US 2003096781 A1 20030522
AI US 2002-232506 A1 20020830 (10)
PRAI US 2001-316666P 20010831 (60)
DT Utility
FS APPLICATION
LREP Chris J. Ullsperger, Ph.D., Bingham McCutchen LLP, Suite 1800, Three Embarcadero Center, San Francisco, CA, 94111
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 2224
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for treating and diagnosing Kaposi's sarcoma are provided. In one embodiment the invention provides a method of treating disease wherein the method comprises modulation of IL-8. The disease to be treated may be a disease such as Kaposi's sarcoma. In one embodiment, the invention comprises administering a therapeutic composition comprising IL-8 antisense oligonucleotides. The invention also provides a method of diagnosing Kaposi's sarcoma wherein the method comprises measuring the expression level of IL-8.

L23 ANSWER 71 OF 77 USPATFULL on STN
AN 2003:140406 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003096247 A1 20030522
AI US 2001-986 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L23 ANSWER 72 OF 77 USPATFULL on STN
AN 2003:133926 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003092011 A1 20030515
US 6794363 B2 20040921
AI US 2001-489 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806

US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25607
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L23 ANSWER 73 OF 77 USPATFULL on STN
AN 2003:37603 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027248 A1 20030206
AI US 2001-924340 A1 20010806 (9)
PRAI US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP GENSET, JOHN LUCAS, PHD, J.D., 10665 SORRENTO VALLEY RD, SAN DIEGO, CA, 92121
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L23 ANSWER 74 OF 77 USPATFULL on STN
AN 2003:37516 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027161 A1 20030206
AI US 2001-992600 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
CLMN Number of Claims: 13

ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L23 ANSWER 75 OF 77 USPATFULL on STN
AN 2002:16829 USPATFULL
TI METHOD FOR MEASURING THYROGLOBULIN
IN KATO, RYOJI, NAGANO, JAPAN
MARUYAMA, MASAYUKI, NAGANO, JAPAN
NAKAMURA, KENJI, HYOUGO, JAPAN
SHIMIZU, KAYOKO, HYOUGO, JAPAN
SATOMURA, SHINJI, OSAKA, JAPAN
PA WAKO PURE CHEMICAL INDUSTRIES, LTD., OSAKA, JAPAN (non-U.S. corporation)
PI US 2002009709 A1 20020124
AI US 1999-340196 A1 19990628 (9)
PRAI JP 1998-199794 19980630
DT Utility
FS APPLICATION
LREP ARMSTRONG,WESTERMAN, HATTORI,, MCLELAND & NAUGHTON, LLP, 1725 K STREET, NW, SUITE 1000, WASHINGTON, DC, 20006
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1225
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for measuring thyroglobulin(s), comprising using each one or more kinds of proteins capable of binding to a constant region of thyroglobulin(s) and proteins capable of specifically binding to a specific sugar chain structure of thyroglobulin(s) having the specific sugar chain structure, and the method of determining a malignancy of thyroid tumor, a reagent thereof using the obtained by the method for measuring thyroglobulin(s).

L23 ANSWER 76 OF 77 USPATFULL on STN
AN 97:63874 USPATFULL
TI Molecular analytical release tags and their use in chemical analysis
IN Giese, Roger W., Quincy, MA, United States
Abdel-Baky, Samy, Braintree, MA, United States
Allam, Kariman, Braintree, MA, United States
PA Northeastern University, Boston, MA, United States (U.S. corporation)
PI US 5650270 19970722
AI US 1990-496251 19900320 (7)
RLI Continuation-in-part of Ser. No. US 1987-45089, filed on 4 May 1987, now abandoned which is a continuation of Ser. No. US 1982-344394, filed on 1 Feb 1982, now patented, Pat. No. US 4709016
DT Utility
FS Granted
EXNAM Primary Examiner: Higel, Floyd D.
LREP Weingarten, Schurgin, Gagnebin & Hayes LLP
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 2434
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Analytical reagents designated "release tags", for labeling molecular species with a highly detectable signal group which can be released in the form of a volatile compound at a desired point in an analytical procedure. In one embodiment, the release tags have the formula

(SgCo).sub.x L(Rx).sub.r

wherein each Sg is a signal group bearing one or more electronegative substituents, L is any of a wide variety of groups which when attached to a carbonyl group form a readily cleaved linkage, each COL moiety is a release group which upon scission releases signal group Sg in the form of a volative compound, and each Rx is a reactivity group for attaching the release tag compound to a molecular species to be labeled. In a second embodiment, the release tags have the formula

SgReRx

wherein Sg and Rx are defined as above and Re is a release group which is an olefin, α-hydroxy ketone or vicinal diol. Conjugates of the release tag compounds and assay methods employing them are also disclosed.

L23 ANSWER 77 OF 77 USPATFULL on STN
AN 87:9573 USPATFULL
TI Method and system for detection of complement pathway activation
IN Cooper, Neil, San Diego, CA, United States
Mayes, James T., La Jolla, CA, United States
PA Scripps Clinic and Research Foundation, La Jolla, CA, United States (U.S. corporation)
PI US 4642284 19870210
AI US 1983-503705 19830613 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Rosen, Sam
LREP Dressler, Goldsmith, Shore, Sutker & Milnamow, Ltd.
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1639
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method and system for detecting and preferably measuring the presence of an activated complement complex in a sample is discussed. The presence of such an activated complex is indicative of complement pathway activation and includes a first complement component and a second complement component. The method uses a first binding agent specific to the first complement component and a second binding agent specific to the second complement component which when bound with the complex forms an aggregate. The second specific binding agent includes a label whose presence is used to detect and measure the amount of aggregate and therefore activated complex in a sample. An assay system and aggregate for use in an assay system are also discussed.